pid	title	sent	label	prob
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus.	1	0.7704122673047837
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China.	-1	0.5
fway438n	Sanofi, BARDA team for coronavirus vaccine	Sanofi Pasteur is working with the US Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine against the novel coronavirus, known as severe acute respiratory syndrome-CoV-2, which as of Feb. 20 had infected more than 75,000 people and killed more than 2,100.	1	0.7704122673047837
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Coronavirus disease 2019 (COVID-19) associated pneumonia caused by severe acute respiratory coronavirus 2 (SARS-COV-2) was first reported in Wuhan, China in December 2019.	1	0.7704122673047837
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	 Background Coronaviruses pose a serious threat to global health as evidenced by Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and COVID-19.	1	0.7704122673047837
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak.	1	0.8387733020104001
5sfwyn9g	Coronavirus 2019-nCoV: Is the genie already out of the bottle?	Coronavirus 2019-nCoV: Is the genie already out of the bottle?	1	0.7704122673047837
x95h80nq	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China	 On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO).	1	0.7704122673047837
eahhf7yh	COVID-19 pneumonia: what has CT taught us?	COVID-19 pneumonia: what has CT taught us?	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The 2019 novel coronavirus (COVID19 / Wuhan coronavirus), officially named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a positive-sense single-stranded RNA coronavirus.	1	0.7704122673047837
lg45goe2	Gilead and Moderna lead on coronavirus treatments	wo US biotech firms have positioned themselves as front-runners fighting the novel coronavirus, called SARS-CoV-2.	1	0.7704122673047837
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	Coronavirus testing, mortality, vaccine development, containment vs mitigation, and more.	1	0.7704122673047837
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified in Wuhan, China in late December 2019.	1	0.7704122673047837
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe.	1	0.7704122673047837
cko9o39t	Novel coronavirus is putting the whole world on alert	Novel coronavirus is putting the whole world on alert	1	0.7704122673047837
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses.	1	0.7704122673047837
2m6ks6nd	The outbreak of Coronavirus Disease 2019 (COVID-19)‚ÄîAn emerging global health threat	 The outbreak of Coronavirus Disease 2019 (COVID-19) causing novel coronavirus-infected pneumonia (NCIP), has affected the lives of 71,429 people globally.	1	0.7704122673047837
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Background: COVID-19 outbreak is spreading globally.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	The discovery of epitopes is helpful to the development of SARS-CoV-2 vaccine.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world.	1	0.7704122673047837
mu413rvc	Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model	With sensitivity of the Polymerase Chain Reaction (PCR) test used to detect the presence of the virus in the human host, the global health community has been able to record a great number of recovered population.	-1	0.5
rl2qxd03	The SARS-CoV-2 Vaccine Pipeline: an Overview	The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19).	1	0.7704122673047837
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	Coronaviruses are the well-known cause of severe respiratory, enteric and systemic infections in a wide range of hosts including man, mammals, fish, and avian.	1	0.7704122673047837
zpaqd5vd	COVID-19: Knowns, Unknowns, and Questions	The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses.	1	0.7704122673047837
c4pcztdc	Functional Cell Receptors for Human Coronavirus	Viruses infect host cells by binding to receptors on thesurface of cells.	-1	0.5
g9wmlvnq	Voice from China: nomenclature of the novel coronavirus and related diseases	Voice from China: nomenclature of the novel coronavirus and related diseases	1	0.7704122673047837
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	A novel coronavirus was reported to the World Health Organization (WHO) in China on 31 December 2019.	1	0.7704122673047837
oq79dfhr	Structure of novel coronavirus‚Äôs spike protein solved	n a piece of research accomplished with astonishing speed, scientists from the University of Texas at Austin and the National Institutes of Health have released a cryo-electron microscopy (cryo-EM) structure of part of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that has infected tens of thousands of people and killed more than 2,000 since the end of December (Science 2020, DOI: 10.1126/science.abb2507).	1	0.7704122673047837
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	An outbreak of a novel coronavirus (COVID-19 or 2019-CoV) infection has posed significant threats to international health and the economy.	1	0.7704122673047837
ctd9sutv	Is COVID-19 receiving ADE from other coronaviruses?	 One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world.	1	0.7704122673047837
ckay4ufw	MATHEMATICAL PREDICTIONS FOR COVID-19 AS A GLOBAL PANDEMIC	This study shows that the disease free equilibrium (E_0 ) for COVID-19 coronavirus does not satisfy the criteria for a locally or globally asymptotic stability.	1	0.7704122673047837
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives.	1	0.7704122673047837
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	 The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19.	-1	0.5
nzvuugls	Puzzle of highly pathogenic human coronaviruses (2019-nCoV)	Puzzle of highly pathogenic human coronaviruses (2019-nCoV)	1	0.7704122673047837
d52yx420	Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions	Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions	1	0.7704122673047837
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	Since December, 2019, an outbreak of pneumonia caused by the new coronavirus (2019-nCoV) has hit the city of Wuhan in the Hubei Province.	1	0.7704122673047837
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	In late December 2019 a previous unidentified coronavirus, currently named as the 2019 novel coronavirus (2019-nCoV), emerged from Wuhan, China and resulted in a formidable outbreak in many cities in China and expanding globally, including Thailand, Republic of Korea, Japan, USA, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries).	1	0.7704122673047837
c4u0gxp5	The outbreak of COVID-19: An overview	In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries).	1	0.7704122673047837
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	In early December 2019 a cluster of cases of pneumonia of unknown cause was identified in Wuhan, a city of 11 million persons in the People&rsquo;s Republic of China.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Background: At the beginning of the New Year 2020, China alerted the world health organization (WHO) to a cluster of unusual pneumonia cases in Wuhan.	-1	0.5
gchlbnmt	Routine childhood immunization may protect against COVID-19	Routine childhood immunization may protect against COVID-19	-1	0.5
luxgc7st	From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ‚Äì Call for a One Health approach	Human coronaviruses continue to pose a threat to human health.	1	0.7704122673047837
fjmchbew	The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR	The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR	1	0.9127579776651258
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	An outbreak of a novel coronavirus, now formally named severe acute respiratory syndrome coronavirus 2 (SARS‚ÄêCoV‚Äê2) and causing coronavirus disease 2019 (COVID‚Äê19), emerged in the city of Wuhan in Hubei province in central China in December 2019.	1	0.7704122673047837
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic.	1	0.7704122673047837
uze6ze8o	SARS to novel coronavirus ‚Äì old lessons and new lessons	The response to the novel coronavirus outbreak in China suggests that many of the lessons from the 2003 SARS epidemic have been implemented and the response improved as a consequence.	1	0.7704122673047837
xvkjy1bh	A commentary on ‚ÄúWorld Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19)‚Äù	A commentary on ‚ÄúWorld Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19)‚Äù	1	0.7704122673047837
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	 This paper concerns study of the genome of the Wuhan Seafood Market isolate believed to represent the causative agent of the disease COVID-19.	-1	0.5
99doz9m6	Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions	On 31 December, 2019, a cluster of 27 pneumonia cases of unknown etiology was reported by Chinese health authorities in Wuhan City (China) [...].	-1	0.5
6p23qxb8	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies	1	0.7704122673047837
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world.	1	0.7704122673047837
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Finding vaccine or specific antiviral treatment for global pandemic of virus diseases (such as the ongoing COVID-19) requires rapid analysis, annotation and evaluation of metagenomic libraries to enable a quick and efficient screening of nucleotide sequences.	-1	0.5
ju2en6n0	What is the role of rheumatologists in the era of COVID-19?	What is the role of rheumatologists in the era of COVID-19?	-1	0.5
y29kct7v	Potential Treatments for COVID-19; a Narrative Literature Review	SARS-CoV-2 is a newly emerging human infectious coronavirus that causes COVID-19, which has been recognized as a pandemic by the World Health Organization (WHO) on March 11(th).	1	0.7704122673047837
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	ABSTRACTThe respiratory syndrome caused by a new type of coronavirus has been emerging from China and caused more than 1000 death globally since December 2019.	1	0.7704122673047837
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections.	1	0.7704122673047837
oxs4o9xe	2019-nCoV in context: lessons learned?	2019-nCoV in context: lessons learned?	-1	0.5
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	In their Journal article, Li and colleagues3 provide a detailed clinical and epidemiologic description of the first 425 cases reported in the epicenter of the outbreak: the city of Wuhan in Hubei province, China.	-1	0.5
4pxmr5cw	Emergency response to the outbreak of COVID-19: the Korean case	 This letter aims to describe how Korea can improve its emergency response to the outbreak of COVID-19.	-1	0.5
9igk3ke1	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	 It is an ugly fact that a significant amount of the world's population will contract SARS-CoV infection with the current spreading.	-1	0.5
l6rqsqs2	Science in the fight against the novel coronavirus disease	Science in the fight against the novel coronavirus disease	1	0.7704122673047837
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Background: Twitter has been used to track trends and disseminate health information during viral epidemics.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	 The current pandemic of Coronavirus Disease 2019 (COVID-19) has focused the attention of medical-care providers away from non-life-threatening diseases, including infertility.	1	0.7704122673047837
15rpskir	Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management	Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management	-1	0.5
pp6hb4q5	COVID-19: Yet another coronavirus challenge in transplantation	COVID-19: Yet another coronavirus challenge in transplantation	1	0.7704122673047837
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	A possible threat in the ophthalmology clinic While the 2019-nCoV transmission route is still unknown, countries have been preparing measures based on past experiences with coronaviruses namely SARS-CoV and MERS-CoV.	1	0.7704122673047837
u0t2ezk8	An Imperative Need for Research on the Role of Environmental Factors in Transmission of Novel Coronavirus (COVID-19)	An Imperative Need for Research on the Role of Environmental Factors in Transmission of Novel Coronavirus (COVID-19)	1	0.7704122673047837
ju35nyir	Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential	[Image: see text] The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics.	1	0.8387733020104001
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	A novel pneumonia-associated respiratory syndrome named coronavirus disease-2019 (COVID-19), which caused by SARS-CoV-2 and broken in Wuhan, China in the end of 2019.	1	0.7704122673047837
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	On December 31, 2019, Chinese health officials reported a cluster of cases of acute respiratory illness in persons associated with the Hunan seafood and animal market in the city of Wuhan, Hubei Province, in central China.	-1	0.5
5fg87lvu	The SARS-CoV-2 outbreak: what we know	 There is a current worldwide outbreak of the novel coronavirus Covid-19 (coronavirus disease 2019; the pathogen called SARS-CoV-2; previously 2019-nCoV), which originated from Wuhan in China and has now spread to 6 continents including 66 countries, as of 24:00 on March 2, 2020.	1	0.7704122673047837
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health.	1	0.7704122673047837
t7cdmy3e	Inside China and COVID-19: Questions and answers	Inside China and COVID-19: Questions and answers	-1	0.5
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020.	1	0.7704122673047837
epcel2ez	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future	 At the end of December 2019, a novel coronavirus, 2019-nCoV, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China, which has posed great threats to public health and attracted enormous attention around the world.	1	0.7704122673047837
ork04nx8	The novel Coronavirus (SARS-CoV-2) is a one health issue	The novel Coronavirus (SARS-CoV-2) is a one health issue	1	0.7704122673047837
9nc58u1h	Outbreak of COVID-19 ‚Äì an urgent need for good science to silence our fears?	Outbreak of COVID-19 ‚Äì an urgent need for good science to silence our fears?	-1	0.5
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	An ongoing outbreak of pneumonia caused by a novel coronavirus, currently designated as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was reported recently.	1	0.7704122673047837
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	 Novel Corona Virus Disease (COVID-19) originating from China has rapidly crossed borders, infecting people throughout the whole world.	-1	0.5
971d0sir	The SARS-CoV-2 outbreak from a one health perspective	 The SARS-CoV-2 is a new human coronavirus candidate recently detected in China that is now reported in people on inhabited continents.	1	0.7704122673047837
tpmgrk14	New threat: 2019 novel Coronavirus infection and infection control perspective in Turkey	New threat: 2019 novel Coronavirus infection and infection control perspective in Turkey	1	0.7704122673047837
1a8uevk8	A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence	 The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease.	1	0.7704122673047837
uyu2buo1	Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?	SARS-CoV-2, SARS and MERS are all enveloped viruses that can cause acute respiratory syndrome.	-1	0.5
8eh90ber	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib	 COVID-19 emerges as a pandemic disease with high mortality.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Direct-acting antivirals are effective tools to control viral infections.	-1	0.5
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	A novel coronavirus has been identified as the causative agent of a massive outbreak of atypical pneumonia originating at Wuhan, Hubei province, China.	1	0.7704122673047837
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China).	1	0.7704122673047837
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	 The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency.	1	0.7704122673047837
6ghu34m1	Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report	Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report	-1	0.5
dpcpg5c1	Nucleotide Analogues as Inhibitors of Viral Polymerases	Coronaviruses such as the newly discovered virus from Wuhan, China, 2019-nCoV, and the viruses that cause SARS and MERS, have resulted in regional and global public health emergencies.	1	0.7704122673047837
62huo2cu	COVID-19 and diabetes: Can DPP4 inhibition play a role?	COVID-19 and diabetes: Can DPP4 inhibition play a role?	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	SARS-CoV-2 is the etiological agent responsible for the COVID-19 outbreak in Wuhan.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	Wuhan coronavirus, called 2019-nCoV, is a newly emerged virus that infected more than 9692 people and leads to more than 213 fatalities by January 30, 2020.	1	0.7704122673047837
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed.	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	The global spread of SARS-CoV-2 requires an urgent need to find effective therapeutics for the treatment of COVID-19.	1	0.6078988077281519
hnoovm03	Convalescent plasma as a potential therapy for COVID-19	Convalescent plasma as a potential therapy for COVID-19	-1	0.5
hoibwxms	Methanol Poisoning Emerging as the Result of COVID-19 Outbreak; Radiologic Perspective	Methanol Poisoning Emerging as the Result of COVID-19 Outbreak; Radiologic Perspective	-1	0.5
2wnsfkls	A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab	A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab	1	0.7704122673047837
vbgf50os	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	Three anti-HIV drugs, ritonavir, lopinavir and darunavir, might have therapeutic effect on coronavirus disease 2019 (COVID-19).	1	0.7704122673047837
75cotmn2	Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients	 The SARS-CoV-2 (Covid-19) coronavirus pandemic is evolving very quickly and means a special risk for both immunosuppressed and comorbid patients.	1	0.7704122673047837
t6zf5k99	The Novel Coronavirus ‚Äì A Snapshot of Current Knowledge	Another animal to human transmission of a coronavirus occurred in December 2019 on a live animal market in the Chinese city of Wuhan causing an epidemic in China, reaching now different continents.	1	0.7704122673047837
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	: Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs.	-1	0.5
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	 Viral respiratory diseases such as the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), always pose severe threat to people.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths.	-1	0.5
1u12qr97	Advance of promising targets and agents against 2019-nCoV in China	Advance of promising targets and agents against 2019-nCoV in China	-1	0.5
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	 The recent outbreak of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in December 2019 raised global health concerns.	1	0.7704122673047837
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	ABSTRACT The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue.	1	0.7704122673047837
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	The infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide.	1	0.7704122673047837
2hgwa6pq	A potential role for integrins in host cell entry by SARS-CoV-2	‚Ä¢ Integrin may act as an alternative receptor for SARS-CoV-2 and could be implicated in its transmission and pathology.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	 Aims To analyze the potential mechanism of cardiovascular dysfunctions induced by Coronavirus Disease 2019 (COVID-19) and to evaluate more effective therapeutic pathways for patients with cardiovascular diseases.	1	0.7704122673047837
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	 The novel coronavirus infection that initially found at the end of 2019 has attracted great attention.	1	0.7704122673047837
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Objective: To analyze the clinical characteristics of patients with novel coronavirus pneumonia in Kunming City, and to study the correlation between nutritional status and immune function.	1	0.7704122673047837
nxfr24sp	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	Coronavirus disease 2019 (COVID-19) is a highly infective disease caused by the severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2).	1	0.7704122673047837
9hxihlw9	Arguments in favour of remdesivir for treating SARS-CoV-2 infections	Arguments in favour of remdesivir for treating SARS-CoV-2 infections	-1	0.5
bnuda70x	COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us	COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us	1	0.7704122673047837
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	 Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19).	1	0.7704122673047837
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	 The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide.	1	0.7704122673047837
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	ABSTRACTThe outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019.	1	0.7704122673047837
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	2019-nCoV is a newly identified coronavirus with high similarity to SARS-CoV.	1	0.7704122673047837
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	 The coronavirus disease-19 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus that was first detected at the end of December 2019.	1	0.7704122673047837
6y9n69g5	Drug targets for corona virus: A systematic review	The 2019-novel coronavirus (nCoV) is a major source of disaster in the 21(th) century.	1	0.7704122673047837
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months.	1	0.7704122673047837
stnjl8f8	Current status of treatment for 2019 novel coronavirus pneumonia	2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV).	1	0.7704122673047837
2cuts3d9	Chloroquine for the 2019 novel coronavirus SARS-CoV-2	Chloroquine for the 2019 novel coronavirus SARS-CoV-2	1	0.7704122673047837
yf5g53a9	Teicoplanin: an alternative drug for the treatment of COVID-19?	ABSTRACT In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency.	1	0.7704122673047837
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	ABSTRACT Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China.	1	0.7704122673047837
9q3lmsd3	Chloroquine and hydroxychloroquine as available weapons to fight COVID-19	Chloroquine and hydroxychloroquine as available weapons to fight COVID-19	-1	0.5
sjyrr2bn	COVID-19: A promising cure for the global panic	 The novel Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, which is the causative agent of a potentially fatal disease that is of great global public health concern.	1	0.7704122673047837
1yka7ej9	The within-host viral kinetics of SARS-CoV-2	In this work, we use a within-host viral dynamic model to describe the SARS-CoV-2 kinetics in host.	-1	0.5
mf0lgrlp	No evidence supports the use of ether and chloroform inhalation for treating COVID-19	No evidence supports the use of ether and chloroform inhalation for treating COVID-19	-1	0.5
9jnixy2b	Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)	 As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the ‚Äúoff-label‚Äù repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which has the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death.	1	0.9127579776651258
xrsh3hn2	Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment	Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment	1	0.7704122673047837
804r5xzd	Drug treatment options for the 2019-new coronavirus (2019-nCoV)	Drug treatment options for the 2019-new coronavirus (2019-nCoV)	1	0.7704122673047837
nlsna66a	Strategies against the novel coronavirus: Possible applications of the experimental Ebola drug remdesivir are being tested	Strategies against the novel coronavirus: Possible applications of the experimental Ebola drug remdesivir are being tested	1	0.7704122673047837
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	An outbreak of new SARS-like viral in Wuhan, China has been named 2019-nCoV.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	Steroid compounds, which are expected to have dual functions in blocking host inflammation and MERS-CoV replication, were screened from a chemical library.	-1	0.5
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	Early batches of a kit developed by the US government to diagnose the novel coronavirus infection have been plagued by problems that initially limited their use and cast doubt on their accuracy.	1	0.7704122673047837
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	Many pathogens take advantage of the dependence of the host on the interaction of hundreds of extracellular proteins with the glycosaminoglycans heparan sulfate to regulate homeostasis and use heparan sulfate as a means to adhere and gain access to cells.	-1	0.5
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since.	1	0.7704122673047837
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) was identified from respiratory illness patients in Wuhan, Hubei Province, China, which has recently emerged as a serious threat to the world public health.	1	0.7704122673047837
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (previously called 2019 novel coronavirus (2019-nCoV) is the causative agent of coronavirus disease 2019 (COVID-19), a disease recently declared a global public health emergency by the World Health Organization.	1	0.7704122673047837
5i2dxg8z	The 2019 novel coronavirus resource	An ongoing outbreak of a novel coronavirus infection in Wuhan, China since December 2019 has led to 31,516 infected persons and 638 deaths across 25 countries (till 16:00 on February 7, 2020).	1	0.7704122673047837
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	: Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) infection has been widely spread.	1	0.7704122673047837
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	: Since early December 2019, the 2019 novel coronavirus disease (COVID-19) has caused pneumonia epidemic in Wuhan, Hubei province of China.	1	0.7704122673047837
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Objective: To analyze the clinical characteristics of cases of novel coronavirus pneumonia and a preliminary study to explore the relationship between different clinical classification and liver damage.	1	0.7704122673047837
1g0mz73b	Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?	Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?	-1	0.5
1cc9ig04	Replication of SARS-CoV-2 in human respiratory epithelium	SARS-CoV-2 emerged by the end of 2019 to rapidly spread in 2020.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	 BackgroundÔºöSince December 2019, Severe acute respiratory syndrome coronavirus 2ÔºàSARS-CoV-2Ôºâ-infected disease (Coronavirus Disease 2019ÔºåCOVID-19) emerged in Wuhan , ChinaÔºåand rapidly spread throughout ChinaÔºåeven throughout the world.	1	0.7704122673047837
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	 Since the outbreak of the new coronavirus epidemic, novel coronavirus has infected nearly 100,000 people in more than 110 countries.	1	0.7704122673047837
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Background: To identify safe and effective medical countermeasures (e.g., antivirals/antibodies) to address the current outbreak of a novel coronavirus (COVID-19) Methods: Comprehensive literature searches were developed by an experienced librarian for MEDLINE, EMBASE, the Cochrane Library, and biorxiv.org/medrxiv.org; additional searches for ongoing trials and unpublished studies were conducted in clinicaltrials.gov and the Global Infectious Diseases and Epidemiology Network (GIDEON).	1	0.7704122673047837
8xmcljal	Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe	Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe	1	0.7571549044589717
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	We firstly reported a case of acute myelitis in a SARS-CoV-2-infected patient.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	: A novel coronavirus (2019-nCoV) has raised world concern since it emerged in Wuhan Hubei China in December, 2019.	1	0.7704122673047837
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	As of today, the intermediate host of 2019-nCoV has not been determined.	-1	0.5
hxaix2al	Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed	Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed	1	0.7704122673047837
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	 Background Cancer patients are regarded as a highly vulnerable group in the current Coronavirus Disease 2019 (COVID-19) pandemic.	1	0.7704122673047837
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Objective In this study we execute a rational screen to identify Chinese medical herbs that are commonly used in treating viral respiratory infections and also contain compounds that might directly inhibit 2019 novel coronavirus (2019-nCoV), an ongoing novel coronavirus that causes pneumonia.	1	0.7704122673047837
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	 The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2.	1	0.7704122673047837
fpfl5hco	China empowers Internet hospital to fight against COVID-19	China empowers Internet hospital to fight against COVID-19	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	 Corona virus disease 2019 SARS-CoV-2 (COVID-19) is a zoonotic virus causing a variety of severe of respiratory diseases.	-1	0.5
wl121lg4	Molecular immune pathogenesis and diagnosis of COVID-19	 Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	1	0.7704122673047837
02q9y011	Variable Macro X Domain of SARS-CoV-2 Retains the Ability to Bind ADP-ribose	ABSTRACTThe virus that causes COVID-19, SARS-CoV-2, has a large RNA genome that encodes numerous proteins that might be targets for antiviral drugs.	-1	0.5
yd7tu7u4	Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines	Starting from December 2019, a novel coronavirus, named 2019-nCoV, was found to cause Severe Acute Respiratory (SARI) symptoms and rapid pandemic in China.	1	0.7704122673047837
tun1ndt4	Working through the COVID-19 outbreak: Rapid review and recommendations for MSK and allied heath personnel	 The coronavirus (COVID-19) pandemic has caused the world to undergo unprecedented change in a short space of time.	1	0.7704122673047837
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	: We aimed to report the clinical characteristics of imported coronavirus disease-19 (COVID-19) in Jiangsu Province.	1	0.7704122673047837
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Background: SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs.	1	0.7704122673047837
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	There is a high mortality and long hospitalization period for severe cases with 2019 novel coronavirus disease (COVID-19) pneumonia.	1	0.7704122673047837
5cw1ycyh	Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)	Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)	1	0.7704122673047837
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in China, in December, 2019, now affects the whole world.	1	0.7704122673047837
hylue5wq	Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines	Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines	1	0.7704122673047837
vgkiadky	COVID-19: Gastrointestinal Manifestations and Potential Fecal‚ÄìOral Transmission	COVID-19: Gastrointestinal Manifestations and Potential Fecal‚ÄìOral Transmission	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	 Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern.	1	0.7704122673047837
penb65x7	Liver injury in COVID-19: management and challenges	SARS-CoV-2 shares 82% genome sequence similarity to SARS-CoV and 50% genome sequence homology to Middle East respiratory syndrome coronavirus (MERS-CoV)‚Äîall three coronaviruses are known to cause severe respiratory symptoms.	1	0.7704122673047837
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	The rapid spread of Coronavirus disease 2019 (COVID-19) presents China with a critical challenge.	1	0.7704122673047837
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	A newly identified novel coronavirus (2019-nCoV) has caused numerous acute respiratory syndrome cases in Wuhan China from December 2019 to Feb 2020.	1	0.7704122673047837
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	1	0.7704122673047837
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	 Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China.	1	0.7704122673047837
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS.	-1	0.5
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally.	-1	0.5
fway438n	Sanofi, BARDA team for coronavirus vaccine	Sanofi will build on work on a vaccine against SARS, another coronavirus that circulated in the early 2000s.	1	0.7704122673047837
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Till date, no vaccine or completely effective drug is available to cure COVID-19.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	SARS Coronavirus (SARS-CoV), MERS Coronavirus (MERS-CoV), and the novel coronavirus, previously dubbed 2019-nCoV, and now officially named SARS-CoV-2, are the causative agents of the SARS, MERS, and COVID-19 disease outbreaks, respectively.	1	0.7704122673047837
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development.	1	0.7704122673047837
x95h80nq	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China	As of 24 January 2020, there were 887 confirmed cases of 2019-nCoV infection, including 26 deaths, reported in China and other countries.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	SARS-CoV-2 causes the contagious COVID19 disease also known as 2019-nCoV acute respiratory disease and has led to the ongoing 2019‚Äì20 pandemic COVID19 outbreak.	-1	0.5
lg45goe2	Gilead and Moderna lead on coronavirus treatments	On Feb. 25, the US National Institutes of Health (NIH) said it had begun a Phase II clinical trial of remdesivir, an experimental small-molecule drug made by Gilead Sciences, for treatment of those infected with SARS-CoV-2.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	The first patients began experiencing symptoms of illness in mid-December 2019.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	Anthony S. Fauci, MD discusses the latest developments in the global spread of COVID-19 and the SARS-CoV-2 virus with JAMA Editor Howard Bauchner, MD.	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	This virus is responsible for the ongoing outbreak that causes severe respiratory illness and pneumonia-like infection in humans.	-1	0.5
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines.	1	0.6078988077281519
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized.	-1	0.5
2m6ks6nd	The outbreak of Coronavirus Disease 2019 (COVID-19)‚ÄîAn emerging global health threat	Originating in China, the disease has a rapid progression to other countries.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Although the risk of infection in the US is currently low, it is important to understand the public perception of risk and trust in sources of information to better inform public health messaging.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	The sequences of the surface protein of SARS-CoV-2 and its proximal sequences were obtained by BLAST, the sequences of the whole genome of SARS-CoV-2 were obtained from the GenBank.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	Genomic analysis revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir.	-1	0.5
mu413rvc	Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model	Therefore, in a bid to answer a burning question of reinfection in the recovered class, the model equations which exhibits the disease-free equilibrium (E_0 ) state for COVID-19 coronavirus was developed in this study and was discovered to both exist as well as satisfy the criteria for a locally or globally asymptotic stability with a basic reproductive number R_0=0 for and endemic situation.	1	0.7704122673047837
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	The scientific interest on coronaviruses increased after the emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) outbreaks in 2002-2003 followed by Middle East Respiratory Syndrome CoV (MERS-CoV).	1	0.7704122673047837
zpaqd5vd	COVID-19: Knowns, Unknowns, and Questions	The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause.	-1	0.5
c4pcztdc	Functional Cell Receptors for Human Coronavirus	Receptor is an important factor affecting host range and interspecific transmission.	-1	0.5
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	The WHO named the disease COVID-19 on 11 February 2020.	-1	0.5
oq79dfhr	Structure of novel coronavirus‚Äôs spike protein solved	The part of the virus imaged, called the spike protein, helps the virus attach to and infect human cells, and the determination of its structure comes just weeks after the virus‚Äôs genome sequence was published.	-1	0.5
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	In the absence of treatment for this virus, there is an urgent need to find alternative methods to control the spread of disease.	-1	0.5
ctd9sutv	Is COVID-19 receiving ADE from other coronaviruses?	One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses.	1	0.7704122673047837
ckay4ufw	MATHEMATICAL PREDICTIONS FOR COVID-19 AS A GLOBAL PANDEMIC	This implies that as a pandemic as declared by WHO (2020) the COVID-19 coronavirus does not have a curative vaccine yet and precautionary measures are advised through quarantine and observatory procedures.	1	0.7704122673047837
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection.	1	0.6078988077281519
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	With the continuous development of the epidemic, it has become a national public health crisis and calls for urgent antiviral treatments or vaccines.	-1	0.5
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	The disease is officially named as the Severe Specific Contagious Pneumonia (SSCP) in 1/15/2019 and is a notifiable communicable disease of the 5 category by the Taiwan CDC, the Ministry of Health.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020).	1	0.7704122673047837
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	Further investigation revealed these cases to result from infection with a newly identified coronavirus, termed the 2019-nCoV.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	After extensive speculation, eventually a new species of coronavirus introduced as the causative pathogen of the disease.	1	0.7704122673047837
luxgc7st	From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ‚Äì Call for a One Health approach	The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 which causes coronavirus disease-2019 (COVID-19), an acute respiratory disease marked the third introduction of a highly pathogenic coronavirus into the human population in the twenty-first century.	1	0.7704122673047837
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	The first cases were noted as a cluster of patients with pneumonia who were all linked to a live animal market, and testing found the presence of a previously unknown coronavirus.	1	0.7704122673047837
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed.	-1	0.5
uze6ze8o	SARS to novel coronavirus ‚Äì old lessons and new lessons	Nevertheless some questions remain and not all lessons have been successful.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	This is to find a short section or sections of viral protein sequence suitable for preliminary design proposal for a peptide synthetic vaccine and a peptidomimetic therapeutic, and to explore some design possibilities.	-1	0.5
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Traditional sequence alignment methods are not suitable and there is a need for fast alignment-free techniques for sequence analysis.	-1	0.5
y29kct7v	Potential Treatments for COVID-19; a Narrative Literature Review	There is still no vaccine or definitive treatment for this virus because its pathogenesis and proliferation pathways are still unknown.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	This new virus, called 2019 novel coronavirus (2019-nCoV) uses the same receptor called Angiotensinconverting enzyme 2 (ACE2) to attack humans as the coronavirus that caused the severe acute respiratory syndrome (SARS) seventeen years ago.	1	0.7704122673047837
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	1	0.7704122673047837
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	Although this information is critical in informing the appropriate response to this outbreak, as the authors point out, the study faces the limitation associated with reporting in real time the evolution of an emerging pathogen in its earliest stages.	-1	0.5
4pxmr5cw	Emergency response to the outbreak of COVID-19: the Korean case	The key finding is that the nation has to shift from a self-interest‚Äìoriented response to a shared-interest‚Äìoriented response.	-1	0.5
9igk3ke1	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	While specific treatment is not yet coming soon, individual risk assessment and management strategies are crucial.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	On January 21, 2020, the CDC activated its Emergency Operations Center and the WHO released its first situation report about coronavirus disease 2019 (COVID-19), sparking significant media attention.	1	0.7704122673047837
wbxtz30s	After corona: there is life after the pandemic	Although infertility does not jeopardize the physical survival of infertile couples, it does jeopardize their future quality of life.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	These viruses transmit primarily through droplets and other bodily secretions.	-1	0.5
ju35nyir	Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential	Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	Unfortunately, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	On January 7, 2020, Chinese health officials confirmed that a novel coronavirus (2019-nCoV) was associated with this initial cluster (1).	1	0.7704122673047837
5fg87lvu	The SARS-CoV-2 outbreak: what we know	Governments are under increased pressure to stop the outbreak spiraling into a global health emergency.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease.	-1	0.5
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients.	1	0.7704122673047837
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	However, there is no specific antiviral treatment or vaccine currently.	-1	0.5
epcel2ez	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future	To date, there are no clinically approved vaccines or antiviral drugs available for these human coronavirus infections.	1	0.7704122673047837
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	However, as SARS-CoV-2 is an emerging virus, we know little about it.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	This phenomenon has led to a massive public reaction; the media has been reporting continuously across borders to keep all informed about the pandemic situation.	-1	0.5
971d0sir	The SARS-CoV-2 outbreak from a one health perspective	The virus shares a high level of identity with some bat coronaviruses and is recognised as a potentially zoonotic virus.	1	0.7704122673047837
1a8uevk8	A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence	The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency.	-1	0.5
uyu2buo1	Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?	Arachidonic acid (AA) and other unsaturated fatty acids (especially eicosapentaenoic acd, EPA and docosahexaenoic acid DHA) are known to inactivate enveloped viruses and inhibit proliferation of various microbial organisms.	-1	0.5
8eh90ber	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib	Development of effective prevention and treatment is an urgent need.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019.	1	0.7704122673047837
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	Involved in the formation of the coronavirus replication complex, the viral main protease (Mpro, also called 3CLpro) represents an attractive target for therapy.	1	0.7704122673047837
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported.	-1	0.5
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases.	1	0.7704122673047837
dpcpg5c1	Nucleotide Analogues as Inhibitors of Viral Polymerases	Based on our molecular insight that the hepatitis C virus and the coronavirus use a similar viral genome replication mechanism, we reasoned that the FDA-approved drug EPCLUSA (Sofosbuvir/Velpatasvir) for the treatment of hepatitis C will also inhibit the above coronaviruses, including 2019-nCoV.	1	0.7704122673047837
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	Specific antiviral drug are urgently needed to treat COVID-19 infections.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	Currently, there is no effective treatment for this epidemic.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV).	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	We developed a data-driven drug repositioning framework, which applies both machine learning and statistical analysis approaches to systematically integrate and mine large-scale knowledge graph, literature and transcriptome data to discover the potential drug candidates against SARS-CoV-2.	-1	0.5
vbgf50os	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	In this study, the structure models of two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteases, coronavirus endopeptidase C30 (CEP_C30) and papain like viral protease (PLVP), were built by homology modeling.	1	0.7704122673047837
75cotmn2	Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients	Knowledge about this growing infection is also increasing although many uncertainties remain, especially in the kidney transplant population.	-1	0.5
t6zf5k99	The Novel Coronavirus ‚Äì A Snapshot of Current Knowledge	This minireview summarizes the research literature on the virological, clinical and epidemiological aspects of this epidemic published until end of February 2020.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	This review focuses on the effects of these drugs on host immunity against COVID-19.	-1	0.5
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	First identified in the late December 2019, in Wuhan, China, a novel coronavirus (2019-nCoV) has rampantly spread to lots of provinces in China, and multiple countries are affected.	1	0.7704122673047837
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	There are currently no registered therapies for treating coronavirus infections.	1	0.7704122673047837
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	The viral 3-chymotrypsin-like cysteine protease (3CLpro) enzyme controls coronavirus replication and is essential for its life cycle.	1	0.7704122673047837
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China.	-1	0.5
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing.	-1	0.5
2hgwa6pq	A potential role for integrins in host cell entry by SARS-CoV-2	‚Ä¢ The spike protein of SARS-CoV-2 acquired a RGD motif known to bind integrins.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Data Synthesis COVID-19 mainly invades the lungs, causing its serious damage.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	So far, the number of infectious cases has increased globally to more than 100 thousand and defined as a pandemic situation, but there are still no ‚Äúspecific drug‚Äù available.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Methods: Clinical data of 36 patients with novel coronavirus pneumonia in isolation area of Kunming Third People's Hospital from January 31 to February 15, 2020 were collected, and the basic situation, clinical characteristics, laboratory examination and CT imaging characteristics were analyzed.	1	0.7704122673047837
nxfr24sp	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	Previous studies of the COVID-19 pneumonia outbreak were based on information from the general population.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries.	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing.	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	We performed a structural analysis of the receptor binding domain (RBD) of spike glycoprotein responsible for entry of coronaviruses into host cells.	1	0.7704122673047837
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	The epidemic has affected various regions of China in different degrees.	-1	0.5
6y9n69g5	Drug targets for corona virus: A systematic review	However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines.	1	0.6078988077281519
stnjl8f8	Current status of treatment for 2019 novel coronavirus pneumonia	At present, there is no specific antiviral drug targeting 2019-nCoV.	-1	0.5
yf5g53a9	Teicoplanin: an alternative drug for the treatment of COVID-19?	Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution.	-1	0.5
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	Despite drastic containment measures, the spread of this virus is ongoing.	-1	0.5
sjyrr2bn	COVID-19: A promising cure for the global panic	The outbreak of COVID-19 is wreaking havoc worldwide due to inadequate risk assessment regarding the urgency of the situation.	-1	0.5
1yka7ej9	The within-host viral kinetics of SARS-CoV-2	Chest radiograph score data are used to estimate the parameters of that model.	-1	0.5
9jnixy2b	Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)	With the possibility that a considerable proportion of the world‚Äôs population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.	1	0.6078988077281519
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	The current state of the epidemic is increasingly serious, and there has been the urgent necessity to develop an effective new drug.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	Within this library, ciclesonide, an inhaled corticosteroid, suppressed human coronavirus replication in cultured cells, but did not suppress replication of respiratory syncytial virus or influenza virus.	1	0.7704122673047837
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	The problems were first reported by the Washington Post, and C&EN learned soon after that the kits contained faulty reagents that led to inconclusive readouts.	-1	0.5
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	Moreover, mucosal epithelia such as that of the respiratory tract are protected by a layer of mucin polysaccharides, which are usually sulfated.	-1	0.5
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	The number of diagnosed cases is more than 40,000 until the submission of this manuscript.	-1	0.5
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	Hower, no approved drugs have been found to effectively inhibit the virus.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	At the moment there is no available drug(s) and vaccine(s) for the treatment or prevention of COVID-19.	-1	0.5
5i2dxg8z	The 2019 novel coronavirus resource	The virus causing this pneumonia was then named as the 2019 novel coronavirus (2019-nCoV) by the World Health Organization.	1	0.7704122673047837
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	We aim to investigate the clinical characteristic and allergy status of patients infected by SARS-CoV-2.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	This study aims to investigate the factors affecting the progression of pneumonia in COVID-19 patients.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Methods: Consecutively confirmed novel coronavirus infection cases admitted to seven designated hospitals during January 23, 2020 to February 8, 2020 were included.	1	0.7704122673047837
1cc9ig04	Replication of SARS-CoV-2 in human respiratory epithelium	At present, it is of utmost importance to understand the virus biology and to rapidly assess the potential of existing drugs and develop new active compounds.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	We try to describe the epidemiological and clinical characteristics of COVID-19 in non-Wuhan areaÔºåand explore its effective treatment.	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	How to face this new coronavirus epidemic outbreak is an important issue.	1	0.7704122673047837
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Title/abstract and full-text screening, data abstraction, and risk of bias appraisal were carried out by single reviewers.	-1	0.5
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	A 66-year-old man with COVID-19 was admitted with acute flaccid paralysis of bilateral lower limbs and urinary and bowel incontinence.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	The infection may result into severe pneumonia with clusters illness onsets.	-1	0.5
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	Considering that intermediate hosts are generally mammals [5], they are likely the living mammals sold in the South China seafood market.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	To date, the clinical characteristics of COVID-19-infected cancer patients are largely unknown.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Methods There were two main steps in the screening process.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East.	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	SARS-CoV-2 is closest to SARS-CoV and MERS-CoV in structure.	-1	0.5
wl121lg4	Molecular immune pathogenesis and diagnosis of COVID-19	The emergence of SARS-CoV-2 has been marked as the third introduction of a highly pathogenic coronavirus into the human population after the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in the twenty-first century.	1	0.7704122673047837
02q9y011	Variable Macro X Domain of SARS-CoV-2 Retains the Ability to Bind ADP-ribose	Some of these proteins, such as the RNA-dependent RNA polymers, helicase and main protease, are well conserved between SARS-CoV-2 and the original SARS virus, but several others are not.	1	0.7704122673047837
yd7tu7u4	Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines	With the hope to identify candidate drugs for 2019-nCoV, we adopted a computational approach to screen for available commercial medicines which may function as inhibitors for the Mpro of 2019-nCoV.	-1	0.5
tun1ndt4	Working through the COVID-19 outbreak: Rapid review and recommendations for MSK and allied heath personnel	This disease has devastated the economy, infringed personal freedom, and has taken a toll on healthcare systems worldwide.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	METHODS: We retrospectively investigated the clinical, imaging, and laboratory characteristics of confirmed cases of COVID-19 with WHO interim guidance in three Grade ‚Ö¢A hospitals of Jiangsu from Jan 22 to Feb 14, 2020.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion.	-1	0.5
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	Therefore, it makes sense to search for a potential biomarker that could rapidly and effectively identify severe cases early.	-1	0.5
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	As of March 8, 2020, more than 105 000 laboratory-confirmed cases and more than 3500 deaths in over 100 countries had been reported.	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	Liver impairment has been reported in up to 60% of patients with SARS3 and has also been reported in patients infected with MERS-CoV.4 At least seven relatively large-scale case studies have reported the clinical features of patients with COVID-19.1 , 5 , 6 , 7 , 8 , 9 , 10 In this Comment, we assess how the liver is affected using the available case studies and data from The Fifth Medical Center of PLS General Hospital, Beijing, China.	-1	0.5
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	As normal capacity of the Chinese hospitals is exceeded, healthcare professionals struggling to manage this unprecedented crisis face the difficult question of how best to coordinate the medical resources used in highly separated locations.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	Its fast spreading to other provinces in China and overseas is very likely causing a pandemic.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	However, these vaccine candidates might lack the induction of complete protection and have safety concerns.	-1	0.5
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges.	-1	0.5
fway438n	Sanofi, BARDA team for coronavirus vaccine	In December 2019, BARDA awarded the firm a $226 million contract to expand manufacturing capacity for use in a potential flu pandemic.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Therefore, an effective vaccine against SARS-COV-2 is crucially needed.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Safe vaccines that rapidly induce potent and long-lasting virus-specific immune responses against these infectious agents are urgently needed.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.	-1	0.5
x95h80nq	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China	Therefore, combating this new virus and stopping the epidemic is a matter of urgency.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The effective countermeasures against SARS-CoV-2 infection requires the design and development of specific and effective vaccine candidate.	-1	0.5
lg45goe2	Gilead and Moderna lead on coronavirus treatments	On the same day, Moderna said it had shipped its experimental coronavirus vaccine to the NIH, which will conduct a Phase I trial to assess its safety.	1	0.7704122673047837
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses.	1	0.7704122673047837
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	- What's the difference between COVID-19 and SARS-CoV-2?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Due to the increasing number of cases in China and outside China, the WHO declared coronavirus as a global health emergency.	1	0.7704122673047837
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection.	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Therefore, the present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection.	-1	0.5
2m6ks6nd	The outbreak of Coronavirus Disease 2019 (COVID-19)‚ÄîAn emerging global health threat	Research suggests remarkable genomic resemblance of 2019-nCoV with Severe Acute Respiratory Syndrome (SARS) which has a history of a pandemic in 2002.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	In this study, we surveyed the adult US population to understand their risk perceptions about the COVID-19 outbreak.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	Based on the NCBI Reference Sequence: NC_045512.2, the conformational and linear B cell epitopes of the surface protein were predicted separately by various prediction methods.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely.	-1	0.5
mu413rvc	Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model	Hence, there is a chance of no secondary reinfections from the recovered population as the rate of incidence of the recovered population vanishes, that is, B=0.	-1	0.5
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	This decade‚Äôs first CoV, named 2019-nCoV, emerged from Wuhan, China, and declared as ‚ÄòPublic Health Emergency of International Concern‚Äô on January 30(th), 2020 by the World Health Organization (WHO).	-1	0.5
zpaqd5vd	COVID-19: Knowns, Unknowns, and Questions	We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2.	1	0.7704122673047837
c4pcztdc	Functional Cell Receptors for Human Coronavirus	In December 2019, an outbreak of unexplained pneumonia occurred in Wuhan, Hubei province.	-1	0.5
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	As of 26 February 2020, the disease has been detected on all continents, except for Antarctica.	-1	0.5
oq79dfhr	Structure of novel coronavirus‚Äôs spike protein solved	The breakthrough is a huge step toward developing a vaccine against the virus as well as treatments for COVID-19, the disease that it causes, the researchers say.	-1	0.5
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	Here, we have conducted an online search for all treatment options related to coronavirus infections as well as some RNA virus infection and we have found that general treatments, coronavirus-specific treatments, and antiviral treatments should be useful in fighting COVID-19.	1	0.7704122673047837
ctd9sutv	Is COVID-19 receiving ADE from other coronaviruses?	ADE modulates the immune response and can elicit sustained inflammation, lymphopenia, and/or cytokine storm, one or all of which have been documented in severe cases and deaths.	-1	0.5
ckay4ufw	MATHEMATICAL PREDICTIONS FOR COVID-19 AS A GLOBAL PANDEMIC	Also, the Basic Reproductive number (R_0<1) by Equation (33) shows that there is a chance of decline of secondary infections when the ratio between the incidence rate in the population and the total number of infected population quarantined with observatory procedure.	-1	0.5
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19.	1	0.6078988077281519
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002‚Äì2003 and MERS in 2012.	1	0.7704122673047837
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	The spike protein on the coronavirus envelope is critical for host cell infection and virus vitality.	1	0.7704122673047837
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	SSCP is a potential zoonotic disease with low to moderate (estimated 2-5%) mortality rate.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	It is also named as Severe Pneumonia with Novel Pathogens on January 15, 2019 by the Taiwan CDC, the Ministry of Health and is a notifiable communicable disease of the fifth category.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	The infection moved rapidly through China, spread to Thailand and Japan, extended into adjacent countries through infected persons travelling by air, eventually reaching multiple countries and continents.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Coronavirus disease 2019 (COVID-19) is a name for the disease, and the virus that causes it is known SARS-CoV-2.	1	0.7704122673047837
luxgc7st	From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ‚Äì Call for a One Health approach	This recent emergence of a previously unknown coronavirus in China leads to huge impacts on humans globally.	1	0.7704122673047837
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	Coronaviruses are a group of viruses that affect both animals and humans, and several (OC43, 229E, HKU1 and NL63) are a cause of the common cold.1, 2 However, two coronaviruses have previously caused significant outbreaks associated with more severe disease: the SARS coronavirus in 2002‚Äì2003 and the Middle East respiratory syndrome coronavirus that emerged in 2012.1, 2 Chinese authorities and researchers should be commended for their rapid sharing of viral sequences which enabled laboratories worldwide to develop diagnostic tests within weeks of discovery of the pathogen.3 An Australian laboratory subsequently isolated the virus from a clinical sample (the first to do so outside of China), and rapidly shared this virus with relevant global agencies, further aiding diagnostic, therapeutic and vaccine development efforts.	1	0.7704122673047837
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies.	-1	0.5
uze6ze8o	SARS to novel coronavirus ‚Äì old lessons and new lessons	The national and international response demonstrates the complex link between public health, science and politics when an outbreak threatens to impact on global economies and reputations.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	The project was originally directed towards a use case for the Q-UEL language and its implementation in a knowledge management and automated inference system for medicine called the BioIngine, but focus here remains mostly on the virus itself.	-1	0.5
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Current efforts are focusing on development of specific antiviral drugs.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Information theory and data compression algorithms provide a rich set of mathematical and computational tools to capture essential patterns in biological sequences.	-1	0.5
y29kct7v	Potential Treatments for COVID-19; a Narrative Literature Review	Therefore, in this article, new potential COVID-19 therapies are briefly reviewed.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	Both viruses recognize ACE2 through the spike proteins (S-protein) on their surfaces.	-1	0.5
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	This virus causes acute lung symptoms, leading to a condition that has been named as &ldquo;coronavirus disease 2019&rdquo; (COVID-19).	1	0.7704122673047837
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	Nonetheless, a degree of clarity is emerging from this report.	-1	0.5
4pxmr5cw	Emergency response to the outbreak of COVID-19: the Korean case	Similarly, neighboring nations could form a national framework of networks among stakeholders.	-1	0.5
9igk3ke1	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	The individual preventive and protective measures drive the personal risk of getting the disease.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	How Twitter content and sentiment has evolved in the early stages of any outbreak, including the COVID-19 epidemic, has not been described.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	Human infertility can be caused by a number of factors, some of which are age-dependent, and their effects may become irreversible if appropriate measures are not taken in time to prevent irreversible childlessness.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	In the ophthalmology practice, healthcare workers may be particularly susceptible to these infections.	-1	0.5
ju35nyir	Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential	In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	Also, information regarding the immunological characteristics in COVID-19 patients remains limited.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	As of February 4, 2020, a total of 20,471 confirmed cases, including 2,788 (13.6%) with severe illness,* and 425 deaths (2.1%) had been reported by the National Health Commission of China (2).	-1	0.5
5fg87lvu	The SARS-CoV-2 outbreak: what we know	At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients.	-1	0.5
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 ŒºM, 26.63 ŒºM, 2.55 ŒºM and 0.46 ŒºM, respectively.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV.	-1	0.5
epcel2ez	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future	Intensive research on the novel emerging human infectious coronaviruses is urgently needed to elucidate their route of transmission and pathogenic mechanisms, and to identify potential drug targets, which would promote the development of effective preventive and therapeutic countermeasures.	1	0.7704122673047837
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	In this review, we summarize the key events occurred during the early stage of SARS-CoV-2 outbreak, the basic characteristics of the pathogen, the signs and symptoms of the infected patients as well as the possible transmission pathways of the virus.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	All these things are creating a lot of concern for people leading to heightened levels of anxiety.	-1	0.5
971d0sir	The SARS-CoV-2 outbreak from a one health perspective	We are utilizing the One Health concept to understand the emergence of the virus, as well as to point to some possible control strategies that might reduce the spread of the virus across the globe; thus, containment of such virus would be possible.	-1	0.5
1a8uevk8	A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence	Currently, the research on novel coronavirus is still in the primary stage.	1	0.7704122673047837
uyu2buo1	Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?	The pro-inflammatory metabolites of AA and EPA such as prostaglandins, leukotrienes and thromboxanes induce inflammation whereas lipoxins, resolvins, protectins and maresins derived from AA, EPA and DHA not only suppress inflammation but also enhance would healing and augment phagocytosis of macrophages and other immunocytes and decrease microbial load.	-1	0.5
8eh90ber	TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib	We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease.	-1	0.5
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	We determined the crystal structure of the unliganded Mpro at 1.75 √Ö resolution and used this structure to guide optimization of a series of alpha-ketoamide inhibitors.	-1	0.5
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals.	1	0.7704122673047837
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets.	-1	0.5
dpcpg5c1	Nucleotide Analogues as Inhibitors of Viral Polymerases	To develop broad spectrum anti-viral agents, we further describe a novel strategy to design and synthesize viral polymerase inhibitors, by combining the ProTide Prodrug approach used in the development of Sofosbuvir with the use of 3‚Äô-blocking groups that we have previously built into nucleotide analogues that function as polymerase terminators.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	The main protease (Mpro) of SARS-CoV-2 is a key CoV enzyme that plays a pivotal role in mediating viral replication and transcription, which makes it an attractive drug target.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	However, the viral protease of a coronavirus is well-known to be essential for its replication and thus is an effective drug target.	1	0.7704122673047837
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	The retrospective study using the past SARS-CoV and MERS-CoV data demonstrated that our machine learning based method can successfully predict effective drug candidates against a specific coronavirus.	1	0.7704122673047837
vbgf50os	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	Ritonavir, lopinavir and darunavir were then docked to the models, respectively, followed by energy minimization of the protease-drug complexes.	-1	0.5
75cotmn2	Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients	This manuscript presents a proposal for action with general and specific recommendations to protect and prevent infection in this vulnerable population such as kidney transplant recipients.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	METHODS: Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorŒ± (TNFŒ±) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig.	1	0.6078988077281519
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	The viral outbreaks have stirred panic and emergency on public health around the world and the number of infections continues to rise.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases.	-1	0.5
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	3CLpro is a proven drug discovery target in the case of severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV).	1	0.7704122673047837
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern.	-1	0.5
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	In this study, we used our pretrained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of 2019-nCoV.	-1	0.5
2hgwa6pq	A potential role for integrins in host cell entry by SARS-CoV-2	This motif is absent from other coronaviruses.	1	0.7704122673047837
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Studies found that COVID-19 induced the renin-angiotensin system imbalance, inflammatory storm, hypoxemia and stress response et al, all contributed to hypertension and serious myocardial damage in the process of virus pathogenesis, even increasing mortality in COVID-19 patients.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	Relevant reports have pointed out the novel coronavirus has 80% homology with SARS.	1	0.7704122673047837
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Serum albumin (ALB), prealbumin (PAB), hypersensitive c-reactive protein (hs-crp), CD3T cells, CD4T cells, CD8T cells and normal control group were analyzed.	-1	0.5
nxfr24sp	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	Limited data are available for hemodialysis patients with COVID-19 pneumonia.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Human to human transmission is confirmed for COVID-19 by China a month ago.	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2.	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	Here we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells), for viral inhibition that can effectively degrade SARS-CoV-2 sequences and live influenza A virus (IAV) genome in human lung epithelial cells.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	The RBDs from the two viruses share 72% identity in amino acid sequences, and molecular simulation reveals highly similar ternary structures.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	As the situations evolve, the COVID-19 had been confirmed in many countries, and made a assessment that it can be characterized as a pandemic by the World Health Organization on March 11, 2020.	-1	0.5
6y9n69g5	Drug targets for corona virus: A systematic review	In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV).	1	0.7704122673047837
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS-CoV-2.	-1	0.5
stnjl8f8	Current status of treatment for 2019 novel coronavirus pneumonia	In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease.	1	0.7704122673047837
yf5g53a9	Teicoplanin: an alternative drug for the treatment of COVID-19?	Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro.	1	0.9419295262807463
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans.	1	0.7704122673047837
sjyrr2bn	COVID-19: A promising cure for the global panic	The COVID-19 pandemic has entered a dangerous new phase.	-1	0.5
1yka7ej9	The within-host viral kinetics of SARS-CoV-2	Our result shows that the basic reproductive number of SARS-CoV-2 in host growth is around 3.79.	-1	0.5
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	In previous studies, it was found that the conformation change in CTD1 was the region where SARS-CoV bound to human ACE2.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	The effective concentration of ciclesonide to block SARS-CoV-2 (the cause of COVID-19) replication (EC90) was 6.3 ŒºM.	-1	0.5
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	The Centers for Disease Control and Prevention (CDC) has started an investigation into what exactly went wrong with the tests.	-1	0.5
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	Consequently, the polydisperse, natural products of heparan sulfate and the allied polysaccharide, heparin have been found to be involved and prevent infection by a range of viruses including S-associated coronavirus strain HSR1.	1	0.9127579776651258
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating.	1	0.7704122673047837
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	Since it has been reported that the HIV-1 protease inhibitors can be used as anti-SARS drugs by tegarting SARS-CoV 3CLpro, we choose six approved anti-HIV-1 drugs to investigate their binding interactions between 3CLpro, and to evaluate their potential to become clinical drugs for the new coronavirus pneumonia (COVID19) caused by SARS-CoV-2 infection.	1	0.7704122673047837
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	SARS-CoV-2 spike envelope glycoprotein (S) and main protease (Mpro) are crucial determinants in the virus infectious process and have been recognized as key targets for therapeutics designs.	1	0.6078988077281519
5i2dxg8z	The 2019 novel coronavirus resource	To promote the data sharing and make all relevant information of 2019-nCoV publicly available, we construct the 2019 Novel Coronavirus Resource (2019nCoVR, https://bigd.big.ac.cn/ncov).	1	0.7704122673047837
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	METHODS: Electronical medical records including demographics, clinical manifestation, comorbidities, laboratory data and radiological materials of 140 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection were extracted and analysed.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Associated results will be used to evaluate the prognosis and to find the optimal treatment regimens for COVID-19 pneumonia.	1	0.6078988077281519
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Clinical classification (mild, moderate, severe, and critical) was carried out according to the diagnosis and treatment program of novel coronavirus pneumonia (Trial Fifth Edition) issued by the National Health Commission.	1	0.7704122673047837
1cc9ig04	Replication of SARS-CoV-2 in human respiratory epithelium	While some animal models for such studies are under development, most of the research is carried out in the Vero E6 cells.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	MethodsÔºöRetrospective, single-center case series of the 51 hospitalized patients with confirmed COVID-19 at Chongqing University Three Gorges Hospital in Chongqing, China, from January 20 to February 3, 2020ÔºõThe discharge time was from January 29 to February 11, 2020.	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	Basic reproduction number (R0) is an important parameter in epidemiology; The basic reproduction number of an infection can be thought of as the expected number of cases directly generated by one case in a population where all individuals are susceptible to infection.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Results: 54 studies were included in the review: three controlled trials, 10 cohort studies, seven retrospective medical record/database studies, and 34 case reports or series.	-1	0.5
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	All serum microbiological studies were negative except for SARS-CoV-2 nucleic acid testing.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	Its impacts on public health make it paramount to clarify the clinical features with other pneumonias.	-1	0.5
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	Therefore, strengthening the monitoring of wild mammals is an urgent measure to prevent similar viruses from infecting humans in the future.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Patients and methods In this retrospective cohort study, we included cancer patients with laboratory confirmed COVID-19 from three designated hospitals in Wuhan, China.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	In the first step we conducted a literature search for natural compounds that had been biologically confirmed as against sever acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus.	1	0.7704122673047837
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome.	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	The highly prevalence of COVID-19 is due to the lack onset of symptoms.	-1	0.5
wl121lg4	Molecular immune pathogenesis and diagnosis of COVID-19	In this minireview, we provide a brief introduction of the general features of SARS-CoV-2 and discuss current knowledge of molecular immune pathogenesis, diagnosis and treatment of COVID-19 on the base of the present understanding of SARS-CoV and MERS-CoV infections, which may be helpful in offering novel insights and potential therapeutic targets for combating the SARS-CoV-2 infection.	-1	0.5
02q9y011	Variable Macro X Domain of SARS-CoV-2 Retains the Ability to Bind ADP-ribose	This study examines one of the most novel proteins encoded by SARS-CoV-2, a macrodomain of nonstructural protein 3 (nsp3).	-1	0.5
yd7tu7u4	Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines	Up to 10 commercial medicines that may form hydrogen bounds to key residues within the binding pocket of 2019-nCoV Mpro were identified, which may have higher mutation tolerance than lopinavir/ritonavir and may also function as inhibitors for other coronaviruses with similar Mpro binding sites and pocket structures.	1	0.9127579776651258
tun1ndt4	Working through the COVID-19 outbreak: Rapid review and recommendations for MSK and allied heath personnel	This review aims to highlight aspects of this pandemic with a specific emphasis on musculoskeletal work within the secondary care setting.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Real time RT-PCR was used to detect the new coronavirus in respiratory samples.	1	0.7704122673047837
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Antibody against CD147 could block the infection of SARS-CoV-2.	-1	0.5
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	Clinical samples from 28 cases of COVID-19 (8 severe cases, 20 mild cases) in Zunyi District from January 29, 2020 to February 21, 2020 were collected and otherwise statistically analysed for biochemical markers.	-1	0.5
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	Since SARS-CoV-2 RNA was first detected in a stool specimen of the first reported COVID-19 case in the USA,1 much attention has been paid to the study and reporting of gastrointestinal tract infection of SARS-CoV-2.	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	These data indicate that 2‚Äì11% of patients with COVID-19 had liver comorbidities and 14‚Äì53% cases reported abnormal levels of alanine aminotransferase and aspartate aminotransferase (AST) during disease progression (table).	-1	0.5
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	Responding rapidly to this crisis, the National Telemedicine Center of China (NTCC), located in Zhengzhou, Henan Province, has established the Emergency Telemedicine Consultation System (ETCS), a telemedicine-enabled outbreak alert and response network.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	Since the novel coronavirus has been reported to be capable of endangering thousands of lives, it is extremely important to find out how the coronavirus is transmitted in human organs.	1	0.7704122673047837
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020).	1	0.7704122673047837
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	We then applied the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learning tool to predict COVID-19 vaccine candidates.	-1	0.5
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic.	-1	0.5
fway438n	Sanofi, BARDA team for coronavirus vaccine	Sanofi says the new vaccine will use the same technology.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	This study was conducted to design an effective multiepitope based vaccine (MEV) against SARS-COV-2.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	The coronavirus spike (S) protein, a characteristic structural component of the viral envelope, is considered a key target for vaccines for the prevention of coronavirus infection.	1	0.7704122673047837
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	Supplementary strategies through Google Search and personal communications were used.	-1	0.5
x95h80nq	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China	Here, we focus on advances in research and development of fast diagnosis methods, as well as potential prophylactics and therapeutics to prevent or treat 2019-nCoV infection.	1	0.6078988077281519
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	In the present study we have screened 38 CTL, 42 HTL and 12 B cell epitopes by utilizing different in silico tools.	-1	0.5
lg45goe2	Gilead and Moderna lead on coronavirus treatments	The entire process‚Äîfrom vaccine design, to manufacturing, to shipment‚Äîtook only 7 weeks.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(01:15) - What's the status and accuracy of diagnostic testing in the US?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Nearly 35,000 cases were reported and at least 24 other countries or territories have reported coronavirus cases as early on as February.	1	0.7704122673047837
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication.	1	0.7704122673047837
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison.	1	0.7704122673047837
2m6ks6nd	The outbreak of Coronavirus Disease 2019 (COVID-19)‚ÄîAn emerging global health threat	With evidence of nosocomial spread, a number of diligent measures are being employed to constrain its propagation.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Methods and Findings: We used an online platform to survey 718 adults in the US in early February 2020 using a questionnaire that we developed.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	Furthermore, the conservation of the epitopes, the adaptability and other evolutionary characteristics were also analyzed.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	There is no clinically approved antiviral drug or vaccine available to be used against COVID-19.	-1	0.5
mu413rvc	Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model	Furthermore, numerical simulations were carried to complement the analytical results in investigating the effect of the implementation of quarantine and observatory procedures has on the projection of the further spread of the virus globally.	-1	0.5
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	As on February 4, 2020, 425 deaths reported in China only and one death outside China (Philippines).	-1	0.5
c4pcztdc	Functional Cell Receptors for Human Coronavirus	The pathogen was a new coronavirus, named 2019 NovelCoronavirus (2019-nCoV) by WHO.	1	0.7704122673047837
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	Daily updates on COVID-19 since early February 2020 have made headline news worldwide for much of 2020.	-1	0.5
oq79dfhr	Structure of novel coronavirus‚Äôs spike protein solved	UT Austin‚Äôs Jason McLellan and his colleagues, who have spent many years studying other coronaviruses, had already figured out how to use select	1	0.7704122673047837
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	We suggest that the nutritional status of each infected patient should be evaluated before the administration of general treatments and the current children's RNA virus vaccines including influenza vaccine should be immunized for uninfected people and health care workers.	-1	0.5
ctd9sutv	Is COVID-19 receiving ADE from other coronaviruses?	ADE also requires prior exposure to similar antigenic epitopes, presumably circulating in local viruses, making it a possible explanation for the observed geographic limitation of severe cases and deaths.	-1	0.5
ckay4ufw	MATHEMATICAL PREDICTIONS FOR COVID-19 AS A GLOBAL PANDEMIC	The effort to evaluate the disease equilibrium shows that unless there is a dedicated effort from government, decision makers and stakeholders, the world would hardly be reed of the COVID-19 coronavirus and further spread is eminent and the rate of infection will continue to increase despite the increased rate of recovery because of the absence of vaccine at the moment.	1	0.7704122673047837
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death.	1	0.7704122673047837
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	Previous studies showed that 2019-nCoV is highly homologous to human SARS-CoV and attaches host cells though the binding of the spike receptor binding domain (RBD) domain to the angiotensin-converting enzyme II (ACE2).	-1	0.5
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	Person-to-person transmission may occur through droplet or contact transmission and jeopardized first-line healthcare workers if lack of stringent infection control or no proper personal protective equipment available.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	COVID-19 is a potential zoonotic disease with low to moderate (estimated 2%-5%) mortality rate.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	The very rapid spread of the COVID-19 in China and in many other countries has caused fear among people across the world.	-1	0.5
luxgc7st	From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ‚Äì Call for a One Health approach	Covid-19 is a challenge to global public health.	-1	0.5
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	Information on the new virus and its impact is being updated constantly.	-1	0.5
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies.	-1	0.5
uze6ze8o	SARS to novel coronavirus ‚Äì old lessons and new lessons	The unprecedented measures implemented in China are a bold attempt to control the outbreak ‚Äì we need to understand their effectiveness to balance costs and benefits for similar events in the future.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	However, using Q-UEL systems to access relevant and emerging literature, and to interact with standard publically available bioinformatics tools on the Internet, did help quickly identify sequences of amino acids that are well conserved across many coronaviruses including 2019-nCoV.	1	0.7704122673047837
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19).	1	0.7704122673047837
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	In 2013, our research group (Nagaraj et al., Eur.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	It was found that the S-protein from the SARS coronavirus (SARS-CoV) bind stronger to ACE2 than 2019-nCoV.	1	0.7704122673047837
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security.	-1	0.5
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	The median age of the patients was 59 years, with higher morbidity and mortality among the elderly and among those with coexisting conditions (similar to the situation with influenza); 56% of the patients were male.	-1	0.5
9igk3ke1	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	Among the virus-contracted hosts, their different metabolic status, as determined by their diet, nutrition, age, sex, medical conditions, lifestyle, and environmental factors, govern the personal fate toward different clinical severity of COVID-19, from asymptomatic, mild, moderate, to death.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Objective: To quantify and understand early changes in Twitter activity, content, and sentiment about the COVID-19 epidemic.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	Accordingly, each case of infertility should be evaluated comprehensively to establish its position of priority.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	Firstly, ophthalmologists are extremely reliant on physical examination during patient consultation.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in Œ≥Œ¥ T cells.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	Cases have also been reported in 26 locations outside of mainland China, including documentation of some person-to-person transmission and one death (2).	-1	0.5
5fg87lvu	The SARS-CoV-2 outbreak: what we know	This information should include reports from outbreak site and from laboratories supporting the investigation.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay.	1	0.7571549044589717
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 ŒºM.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	In this report, we generated a novel recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1.	-1	0.5
epcel2ez	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future	Herein, we describe the epidemic and etiological characteristics of 2019-nCoV, discuss its essential biological features, including tropism and receptor usage, summarize approaches for disease prevention and treatment, and speculate on the transmission route of 2019-nCoV.	-1	0.5
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	Furthermore, we also review the current knowledge on the origin and evolution of the SARS-CoV-2.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	Pandemics can lead to heightened levels of stress; Anxiety is a common response to any stressful situation.	-1	0.5
1a8uevk8	A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence	Based on the current published evidence, we systematically summarizes the epidemiology, clinical characteristics, diagnosis, treatment and prevention of knowledge surrounding COVID-19.	-1	0.5
uyu2buo1	Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?	In view of these actions, it is suggested that AA and other unsaturated fatty acids and their metabolites may serve as endogenous anti-viral compounds and their deficiency may render humans susceptible to SARS-CoV-2, SARS and MERS and other similar viruses‚Äô infections.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect.	-1	0.5
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	The main goal of the optimization efforts was improvement of the pharmacokinetic properties of the compounds.	1	0.6078988077281519
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	WHO has named the novel coronavirus disease as COVID-19.	1	0.7704122673047837
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	In an effort to rapidly discover lead compounds targeting Mpro, two compounds (11a and 11b) were designed and synthesized, both of which exhibited excellent inhibitory activity with an IC50 value of 0.05 ŒºM and 0.04 ŒºM respectively.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	Fortunately, the sequence identity of the 2019-nCoV protease and that of severe-acute respiratory syndrome virus (SARS-CoV) is as high as 96.1%.	1	0.7704122673047837
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	METHODS: A 2019-nCoV related pangolin coronavirus GX_P2V/pangolin/2017/ Guangxi was described.	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Our in silico screening followed by wet-lab validation indicated that a poly-ADP-ribose polymerase 1 (PARP1) inhibitor, CVL218, currently in Phase I clinical trial, may be repurposed to treat COVID-19.	-1	0.5
vbgf50os	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	In the simulations, ritonavir can bind to CEP_C30 most suitably, and induce significant conformation changes of CEP_C30; lopinavir can also bind to CEP_C30 suitably, and induce significant conformation changes of CEP_C30; darunavir can bind to PLVP suitably with slight conformation changes of PLVP.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	RESULTS: 89 studies were included.	-1	0.5
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	But the cause and consequence of the pneumonia still remain unknown.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling.	1	0.7704122673047837
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	Recent studies revealed that the genome sequence of SARS-CoV-2 is very similar to that of SARS-CoV.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21.	1	0.7704122673047837
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing a inhibitory potency with Kd of 94.94 nM against the 2019-nCoV 3C-like proteinase, followed by efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM).	-1	0.5
2hgwa6pq	A potential role for integrins in host cell entry by SARS-CoV-2	‚Ä¢ The integrin-binding motif is present at the surface of the spike protein, close to the ACE2 receptor-binding region.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Conclusions In the process of management of COVID-19 infections, close attention should be paid on both lung and cardiovascular damage, especially on those with only symptoms of cardiovascular diseases.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	In the difficulty where new synthesized drug cannot be applied immediately to patients, ‚Äúconventional drug in new use‚Äù has become a feasible solution.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	A simple linear regression analysis of the relationship between proalbumin and T cell subpopulation counts in the blood of patients.	-1	0.5
nxfr24sp	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	This report describes the clinical characteristics of COVID-19 in an in-center hemodialysis patient, as well as our experience in implementing steps to prevent the spread of COVID-19 pneumonia among in-center hemodialysis patients.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths.	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with Kd of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM).	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	We designed and screened a group of CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs for cleaving SARS-CoV-2.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	However, 2019-nCoV has a distinct loop with flexible glycyl residues replacing rigid prolyl residues in SARS-CoV.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	Drugs are the main treatment of COVID-19 patients.	-1	0.5
6y9n69g5	Drug targets for corona virus: A systematic review	We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	The research includes the study of drugs that are already available in the market and being used for other diseases to accelerate clinical recovery, in other words repurposing of existing drugs.	-1	0.5
yf5g53a9	Teicoplanin: an alternative drug for the treatment of COVID-19?	Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells.	1	0.8387733020104001
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease.	-1	0.5
sjyrr2bn	COVID-19: A promising cure for the global panic	When compared with SARS and MERS, COVID-19 has spread more rapidly, due to increased globalization and adaptation of the virus in every environment.	-1	0.5
1yka7ej9	The within-host viral kinetics of SARS-CoV-2	Using the same method we also estimate the basic reproductive number of MERS virus is 8.16 which is higher than SARS-CoV-2.	-1	0.5
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	Although there are mutations of the 2019-nCoV, the binding energy of ACE2 remains high.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	After the eleventh consecutive MERS-CoV passage in the presence of ciclesonide, a resistant mutation was generated, which resulted in an amino acid substitution (A25V) in nonstructural protein (NSP) 15, as identified using reverse genetics.	-1	0.5
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	The CDC designed and manufactured the test kit, which detects the RNA genome of the virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	1	0.7704122673047837
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	Here we use surface plasmon resonance and circular dichroism to measure the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin.	1	0.7571549044589717
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies.	1	0.7704122673047837
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	The molecular docking results indicate that, the 3CLpro of SARS-CoV-2 has a higher binding affinity for all the studied inhibitors than its SARS homologue.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	In the present in silico study, a library of 22 phytochemicals with antiviral activity obtained from PubChem Database was screened for activity against 6lu7 and 6vsb with the PyRX software.	-1	0.5
5i2dxg8z	The 2019 novel coronavirus resource	2019nCoVR features comprehensive integration of genomic and proteomic sequences as well as their metadata information from the Global Initiative on Sharing All Influenza Data, National Center for Biotechnology Information, China National GeneBank, National Microbiology Data Center and China National Center for Bioinformation (CNCB)/National Genomics Data Center (NGDC).	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	RESULTS: An approximately 1:1 ratio of male (50.7%) and female COVID-19 patients was found, with an overall median age of 57.0 years.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	METHODS: Patients tested positive for the COVID-19 based on nucleic acid detection were included in this study.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	The research data were analyzed using SPSS19.0 statistical software.	-1	0.5
1cc9ig04	Replication of SARS-CoV-2 in human respiratory epithelium	Here, we propose fully differentiated human airway epithelium cultures as a model for studies on the SARS-CoV-2.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	The main results and indicators of epidemiology, demography, clinical manifestation, laboratory examination, imaging data and treatment data of 51 patients with covid-19 were collected and analyzed.	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	Epidemiology dynamics is a mathematical model based on a susceptibility-infection-recovery epidemic model.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	These studies included patients with severe acute respiratory syndrome (SARs, n=33), middle east respiratory syndrome (MERS, n=16), COVID-19 (n=3), and unspecified coronavirus (n=2).	1	0.7704122673047837
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	Clinical findings could be ascribed to a post-infectious acute myelitis.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	METHODS: Nineteen 2019-nCoV pneumonia (NCOVID-19) and fifteen other pneumonia patients (NON-NCOVID-19) in out of Hubei places were involved in this study.	-1	0.5
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	More than 1,000 confirmed cases have been reported in China.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	The clinical data were collected from medical records from Jan 13, 2020, to Feb 26, 2020.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Resulting compounds were cross-checked for listing in the Traditional Chinese Medicine Systems Pharmacology Database.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections.	1	0.7704122673047837
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	Our study aimed to present an overview of the virus in terms of structure, epidemiology, symptoms, treatment, and prevention.	-1	0.5
02q9y011	Variable Macro X Domain of SARS-CoV-2 Retains the Ability to Bind ADP-ribose	Although 26% of the amino acids in this SARS-CoV-2 macrodomain differ from those seen in other corona-viruses, the protein retains the ability to bind ADP-ribose, which is an important characteristic of beta coronaviruses, and potential therapeutic target.	1	0.7704122673047837
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	RESULTS: Of the 80 patients infected with COVID-19, 41 patients were female, with a median age of 46.1 years.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.	1	0.6078988077281519
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	Serum urea, creatinine (CREA) and cystatin C (CysC) concentrations in severe COVID-19 patients were significantly higher than those in mild COVID-19 patients (P<0.001), and there were also significant differences in serum direct bilirubin (DBIL), cholinesterase (CHE) and lactate dehydrogenase (LDH) concentrations between severe and mild COVID-19 patients (P<0.05).	-1	0.5
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	According to a study2 including 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in China as of Jan 29, 2020, nausea or vomiting, or both, and diarrhoea were reported in 55 (5¬∑6%) and 42 (3¬∑8%) patients.	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	Patients with severe COVID-19 seem to have higher rates of liver dysfunction.	-1	0.5
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	ETCS is built upon a doctor-to-doctor (D2D) approach, in which health services can be accessed remotely through terminals across hospitals.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	Apart from fever and respiratory complications, gastrointestinal symptoms are observed in some patients with 2019-nCoV but the significance remains undetermined.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10), were predicted to be adhesins, which are crucial to the viral adhering and host invasion.	-1	0.5
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Seven antigenic proteins were taken as targets and different epitopes (B-cell, T-cell and IFN-Œ≥ inducing) were predicted.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Methods We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization domain to mimic the native viral structure.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	A total of 27 studies fulfilled the criteria for review.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The screened epitopes were further validated for their binding with their respective HLA allele binders and TAP (Transporter associated with antigen processing) molecule by molecular docking.	-1	0.5
lg45goe2	Gilead and Moderna lead on coronavirus treatments	The news came just as the US Centers for Disease Control and Prevention warned that US communities should brace for ‚Äúdisruption to everyday life.‚Äù Gilead was able to move quickly because it had previously developed remdesivir to treat the Ebola virus.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	As with the SARS-CoV, infections in children appear to be rare.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(01:58) - What's the case-fatality rate for the virus?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Inter-human transmission was reported in a few countries, including the United States.	-1	0.5
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV.	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	The sequence variations were determined using EMBOSS Needle pairwise sequence alignment tools.	-1	0.5
2m6ks6nd	The outbreak of Coronavirus Disease 2019 (COVID-19)‚ÄîAn emerging global health threat	Hence, the Public Health Emergency of International Concern (PHEIC) has been established by the World Health Organization (WHO) with strategic objectives for public health to curtail its impact on global health and economy.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Our sample was fairly similar to the general adult US population in terms of age, gender, race, ethnicity and education.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	7 epitopes were predicted, including 5 linear epitopes and 2 conformational epitopes, one of the linear and one of the conformational were coincide.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clinical trials, resulted in clinical recovery.	-1	0.5
mu413rvc	Estimation of the probability of reinfection with COVID-19 coronavirus by the SEIRUS model	Result shows that the proportion of infected population in the absence of curative vaccination will continue to grow globally meanwhile the recovery rate will continue slowly which therefore means that the ratio of infection to recovery rate will determine the death rate that is recorded globally and most significant for this study is the rate of reinfection by the recovered population which will decline to zero over time as the virus is cleared clinically from the system of the recovered class.	-1	0.5
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	In a short span of time, the virus spread has been noted in 24 countries.	-1	0.5
c4pcztdc	Functional Cell Receptors for Human Coronavirus	Angiotensin-converting enzyme 2 (ACE2) was found to be the receptor of 2019-nCoV.This review provides a brief overview of human coronavirus receptors and their applications, with a view to providing references for the tracing, cross-species transmission, epidemiological analysis and antiviral and vaccine studies of 2019-nCoV.	1	0.7704122673047837
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	This editorial evaluates risk management based on the Global Health Security (GHS) Index of global health security capabilities in 195 countries.	-1	0.5
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	In addition, convalescent plasma should be given to COVID-19 patients if it is available.	-1	0.5
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 ŒºM).	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province.	1	0.7704122673047837
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	However, the molecular mechanisms of 2019-nCoV binding to human ACE2 and evolution of 2019-nCoV remain unclear.	-1	0.5
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	Currently, there is no definite treatment for SSCP although some drugs are under investigation.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	Person-to-person transmission may occur through droplet or contact transmission and if there is a lack of stringent infection control or if no proper personal protective equipment available, it may jeopardize the first-line healthcare workers.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	In the early stages of this epidemic the case fatality rate is estimated to be approximately 2%, with the majority of deaths occurring in special populations.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	The novel coronavirus outbreak declared a Public Health Emergency of International Concern on 30 January 2020.	1	0.7704122673047837
luxgc7st	From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans ‚Äì Call for a One Health approach	Here, we discuss the COVID-19 outbreak in a one health context, highlighting the need for the implementation of one health measures and practices to improve human health and reduce the emergence of pandemic viruses.	-1	0.5
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	We know that SARS‚ÄêCoV‚Äê2 can cause severe disease, although active surveillance of contacts is required to define the milder end of the disease spectrum and to estimate the true hospitalisation and case fatality ratio.	-1	0.5
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs.	1	0.7704122673047837
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	KRSFIEDLLFNKV was found to be particularly well conserved in this study and corresponds to the region around one of the known cleavage sites of the SARS virus that are believed to be required for virus activation for cell entry.	1	0.7704122673047837
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Phys.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	However, function of a bio-system is often under kinetic, rather than thermodynamic, control.	-1	0.5
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses.	-1	0.5
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	Of note, there were no cases in children younger than 15 years of age.	-1	0.5
9igk3ke1	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	The careful individual assessment for the possible dietary, nutritional, medical, lifestyle, and environmental risks, together with the proper relevant risk management strategies, is the sensible way to deal with the pandemic of SARS-CoV-II.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Design: Observational study.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	Assisted reproductive technology (ART) makes it possible to separate fertilization and pregnancy in time.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	Of particular concern is the proximity between the patient and ophthalmologist during the slit lamp microscope examination.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	In comparison to HD, the Œ≥Œ¥ T cells percentage was decreased.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	As of February 4, 11 cases had been reported in the United States.	-1	0.5
5fg87lvu	The SARS-CoV-2 outbreak: what we know	This paper aggregates and consolidates the epidemiology, clinical manifestations, diagnosis, treatments and preventions of this new type of coronavirus.	1	0.7704122673047837
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2.	-1	0.5
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 ŒºM in combination with emetine at 0.195 ŒºM may achieve 64.9% inhibition in viral yield.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	An ACE2 mutant with low catalytic activity was also used in the study.	-1	0.5
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	We highlight bats as the potential natural reservoir and pangolins as the possible intermediate host of the virus, but their roles are waiting for further investigation.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	This study attempted to assess the knowledge, attitude, anxiety experience, and perceived mental healthcare need among adult Indian population during the COVID-19 pandemic.	-1	0.5
1a8uevk8	A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence	This review in the hope of helping the public effectively recognize and deal with the 2019 novel coronavirus (SARS-CoV-2), and providing a reference for future studies.	1	0.7704122673047837
uyu2buo1	Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?	Hence, oral or intravenous administration of AA and other unsaturated fatty acids may aid in enhancing resistance and recovery from SARS-CoV-2, SARS and MERS infections.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease.	-1	0.5
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	We further describe 1.95- and 2.20-√Ö crystal structures of the complex between the enzyme and the most potent alpha-ketoamide optimized this way.	-1	0.5
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19.	1	0.7704122673047837
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	Significantly, both compounds exhibited potent anti-SARS-CoV-2 infection activity in a cell-based assay with an EC50 value of 0.42 ŒºM and 0.33 ŒºM, respectively.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	We show that the protease inhibitor binding sites of 2019-nCoV and SARS-CoV are almost identical, which means all potential anti-SARS-CoV chemotherapies are also potential 2019-nCoV drugs.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Whether GX_P2X uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA) -mediated silencing of ACE2.	-1	0.5
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Our in vitro assays revealed that CVL218 can exhibit effective inhibitory activity against SARS-CoV-2 replication without obvious cytopathic effect.	-1	0.5
vbgf50os	Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases	It is suggested that the therapeutic effect of ritonavir and lopinavir on COVID-19 may be mainly due to their inhibitory effect on CEP_C30, while ritonavir may have stronger efficacy; the inhibitory effect of darunavir on SARS-CoV-2 and its potential therapeutic effect may be mainly due to its inhibitory effect on PLVP.	1	0.6078988077281519
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19.	1	0.7704122673047837
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	In order to effectively implement the epidemic prevention, early identification and diagnosis is critical to disease control.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products.	-1	0.5
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	Therefore, herein, we analysed the 3CLpro sequence, constructed its 3D homology model, and screened it against a medicinal plant library containing 32,297 potential anti-viral phytochemicals/traditional Chinese medicinal compounds.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24‚Äì3.58.	-1	0.5
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases.	-1	0.5
2hgwa6pq	A potential role for integrins in host cell entry by SARS-CoV-2	‚Ä¢ Integrin binding may be a promising therapeutics target, and should be tested experimentally.	1	0.6078988077281519
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Early identification, timely and effective treatments, maintenance of hemodynamics and electrophysiological stability are of great significance on effective treatment and long-term prognosis.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	The first medication experience of the recovered patients in the US has led remdesivir to be the ‚Äúspecific drug‚Äù.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Results: (1) The patients with new coronavirus pneumonia in Kunming were mainly of common type.	1	0.7704122673047837
nxfr24sp	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	The diagnosis, infection control, and treatment of COVID-19 in hemodialysis patients are discussed in this report, and we conclude with recommendations for how a dialysis facility can respond to COVID-19 based on our experiences.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases.	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases.	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	The approach is effective in reducing respiratory cell viral replication for H1N1 IAV.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	Molecular modeling revealed that 2019-nCoV RBD has a stronger interaction with angiotensin converting enzyme 2 (ACE2).	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	Pharmaceutical service offers drug safety ensurance for COVID-19 patients.	-1	0.5
6y9n69g5	Drug targets for corona virus: A systematic review	The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	The vast complexity in drug design and protocols regarding clinical trials often prohibit developing various new drug combinations for this epidemic disease in a limited time.	-1	0.5
yf5g53a9	Teicoplanin: an alternative drug for the treatment of COVID-19?	This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.	-1	0.5
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1.	1	0.9127579776651258
sjyrr2bn	COVID-19: A promising cure for the global panic	Slowing the spread of the COVID-19 cases will significantly reduce the strain on the healthcare system of the country by limiting the number of people who are severely sick by COVID-19 and need hospital care.	-1	0.5
1yka7ej9	The within-host viral kinetics of SARS-CoV-2	The PRCC method is used to analyze the sensitivities of model parameters and the drug effects on virus growth are also implemented to analyze the model.	-1	0.5
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	The surface glycoprotein of 2019-nCoV was coincident with the CTD1 region of the S-protein by comparing the I-TASSER prediction model with the actual SARS model, which suggests that 2019-nCoV may bind to the ACE2 receptor through conformational changes.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	A recombinant virus with the mutation was also resistant to ciclesonide suppression of viral replication.	-1	0.5
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	The US Food and Drug Administration has approved its use in public health departments nationwide.	-1	0.5
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	The data demonstrate an interaction between the recombinant surface receptor binding domain and the polysaccharide.	-1	0.5
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	We here share the therapeutic experiences of NCP treatment with literature review.	-1	0.5
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	Two docking complexes (indinavir and darunavir) with high docking scores were futher subjected to MM-PBSA binding free energy calculations to detail the molecular interactions between these two proteinase inhibitors and the 3CLpro.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	Six lead compounds with binding energies within the range of -9 to -9.6 Kcal/mol were selected for molecular docking analyses against 6lu7.	-1	0.5
5i2dxg8z	The 2019 novel coronavirus resource	It also incorporates a wide range of relevant information including scientific literatures, news, and popular articles for science dissemination, and provides visualization functionalities for genome variation analysis results based on all collected 2019-nCoV strains.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	All patients were community acquired cases.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Patients were admitted to 3 tertiary hospitals in Wuhan between December 30, 2019, and January 15, 2020.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Quantitative data were expressed as median (interquartile range), and qualitative data were expressed as frequency and rate.	-1	0.5
1cc9ig04	Replication of SARS-CoV-2 in human respiratory epithelium	Further, we also provide basic characteristics of the system.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	The changes of blood routine and biochemical indexes at discharge and admission were compared.	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	Researchers analyzed the epidemiological benefits of different transmission rates for the establishment of effective strategy in prevention and control strategies for epidemic infectious diseases.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	The most common treatment was ribavirin (n=41), followed by oseltamivir (n=10) and the combination of lopinavir/ritonavir (n=7).	1	0.7571549044589717
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	He was receiving treatment with ganciclovir, lopinavir/ritonavir, moxifloxacin, dexamethasone, human immunoglobulin and mecobalamin.	1	0.7571549044589717
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	Both NCOVID-19 and NON-NCOVID-19 patients were confirmed to be infected in throat swabs or/and sputa with or without 2019-nCoV by real-time RT-PCR.	-1	0.5
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	The number of provinces and cities in China as well as other Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa112/5721420 by World Health Organization user on 06 February 2020 countries with confirmed cases are steadily increasing.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Univariate and multivariate analyses were performed to assess the risk factors associated with severe events defined as a condition requiring admission to an intensive care unit, the use of mechanical ventilation, or death.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Compounds meeting both requirements were subjected to absorption, distribution, metabolism and excretion (ADME) evaluation to verify that oral administration would be effective.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed.	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	Conduct the differences of whole genome sequence and some viral proteins to determine the gap and the change alternation of nucleotides and amino acids sequences.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Except for 3 severe patients, the rest of the 77 patients exhibited mild or moderate symptoms.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Methods: All patients received recommended strategy from Diagnosis and Treatment for 2019 Novel Coronavirus Diseases released by National Health Commission of China.	1	0.7704122673047837
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases.	-1	0.5
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	Autopsy studies are crucial to help understand the involvement of COVID-19 in the digestive system; however, to date, there has been only one autopsy report3 for a man aged 85 years with COVID-19, which showed segmental dilatation and stenosis in the small intestine.	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	In a study in The Lancet by Huang and colleagues,5 elevation of AST was observed in eight (62%) of 13 patients in the intensive care unit (ICU) compared with seven (25%) of 28 patients who did not require care in the ICU.	-1	0.5
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	The system architecture of ETCS comprises three major architectural layers: (1) telemedicine service platform layer, (2) telemedicine cloud layer, and (3) telemedicine service application layer.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	The cell receptor angiotensin covering enzyme II (ACE2), which is the major receptor of SARS-nCoV, has been reported to be a cellular entry receptor of 2019-nCoV as well.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Outcomes were followed up until Jan 25, 2020.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.	-1	0.5
m5ho8jqp	SARS-CoV-2 Vaccines: Status Report	Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Highly antigenic and overlapping epitopes were shortlisted.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	In variant constructs, we engineered immune stimulants (RS09 or flagellin, as TLR4 or TLR5 agonists, respectively) into this trimeric design.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The screened epitopes were further utilized to design novel two multi-epitope vaccines (MEVs) composed of CTL, HTL and B cell epitopes overlaps with potential to elicit humoral as well as cellular immune response against SARS-CoV-2.	-1	0.5
lg45goe2	Gilead and Moderna lead on coronavirus treatments	The firm is now launching two of its own Phase III clinical trials of remdesivir, in addition to the [truncated]	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Travel-related cases have been confirmed in multiple countries and regions outside mainland China including Germany, France, Thailand, Japan, South Korea, Vietnam, Canada, and the United States, as well as Hong Kong and Taiwan.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(05:31) - Scientific advances and vaccine development (25:06) - Are current clinical trials providing a picture of treatments?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Neither an effective anti-viral nor a vaccine is currently available to treat this infection.	-1	0.5
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	The patent analysis of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines.	1	0.7704122673047837
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	We found that 69% of the respondents wanted the scientific/public health leadership (either the CDC Director or NIH Director) to lead the US response to COVID-19 outbreak as compared to 14% who wanted the political leadership (either the president or the Congress) to lead the response.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	The epitope D mutated easily, but the other epitopes were very conservative and the epitope C was the most conservative.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV).	1	0.7704122673047837
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	The zoonotic transmission (animal-to-human) is suspected as the route of disease origin.	-1	0.5
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	The GHS Index lists the countries best prepared for an epidemic or pandemic.	-1	0.5
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	In conclusion, we suggest that all the potential interventions be implemented to control the emerging COVID-19 if the infection is uncontrollable.	-1	0.5
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 ŒºM).	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	In this study, we have extensively studied the RBD-ACE2 complex, spike protein, and free RBD systems of 2019-nCoV and SARS-CoV using protein-protein docking and molecular dynamics (MD) simulations.	-1	0.5
c4u0gxp5	Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP)	To promptly identify patients and prevent further spreading, physicians should be aware of travel or contact history for patients with compatible symptoms.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	Currently, there is no definite treatment for COVID-19 although some drugs are under investigation.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	Unfortunately, there is limited experience with coronavirus infections during pregnancy, and it now appears certain that pregnant women have become infected during the present 2019-nCoV epidemic.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Materials and Methods: Several databases such as PubMed, Scopus, Google scholar, and BioRxiv were searched for publications reporting on the novel coronavirus up to 29 February 2020.	1	0.7704122673047837
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	The cases reported to date suggest that most are older adults; it is currently unclear whether comorbidities reflect the age group affected or whether they are risk factors for severe disease.4, 5 Early studies using data before the institution of public health interventions in China suggest that SARS‚ÄêCoV‚Äê2 is as transmissible as SARS coronavirus and probably more transmissible than influenza viruses.6, 7 The timing of infectiousness relative to symptom onset is a particularly important parameter with implications for public health control.	1	0.7704122673047837
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	We demonstrate that most PCR-confirmed SARS-CoV-2 infected individuals seroconverted, as revealed by sensitive and specific in-house ELISAs.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	This sequence motif and surrounding variations formed the basis for proposing a specific synthetic vaccine epitope and peptidomimetic agent.	-1	0.5
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	J.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	To address this issue, we constructed a structural model for complex formed between ACE2 and the S-protein from 2019-nCoV, so that the rate of their association can be estimated and compared with the binding of S-protein from SARS-CoV by a multiscale simulation method.	-1	0.5
73a7uvyz	Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV	The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms.	-1	0.5
9i0a9beo	Covid-19 ‚Äî Navigating the Uncharted	Either children are less likely to become infected, which would have important epidemiologic implications, or their symptoms were so mild that their infection escaped detection, which has implications for the size of the denominator of total community infections.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Setting: Twitter platform.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	Whereas pregnant women infected with coronavirus may have an increased risk of adverse neonatal outcomes, gametes do not transmit COVID-19.	1	0.7704122673047837
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	It has been shown that droplets from a cough or sneeze can be propelled for up to 6?m [8], a range that definitely encompasses the distance between the patient and ophthalmologist.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	Œ≥Œ¥ T cells are able to immediately respond to SARS-CoV-2 infection and upregulate the activation marker CD25.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	On January 30, the World Health Organization (WHO) Director-General declared that the 2019-nCoV outbreak constitutes a Public Health Emergency of International Concern.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time.	-1	0.5
7e8zlt3t	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	The fusion proteins were then characterized.	-1	0.5
plxz5mkg	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat	Finally, the advances in the development of chemotherapeutic options are also briefly summarized.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	An online survey was conducted using a semi-structured questionnaire using a non-probability snowball sampling technique.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated.	-1	0.5
xhachzby	X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of Œ±-Ketoamide Inhibitors	These structures will form the basis for further development of these compounds to antiviral drugs.	-1	0.5
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	Hence, we performed a search in March 2020 of the clinicaltrials.gov database.	-1	0.5
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	The X-ray crystal structures of SARS-CoV-2 Mpro in complex with 11a and 11b were determined at 1.5 √Ö resolution, respectively.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	Here, we report a family of potential 2019-nCoV drugs generated by a machine intelligence-based generative network complex (GNC).	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection.	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	In addition, we showed that CVL218 is able to suppress the CpG-induced IL-6 production in peripheral blood mononuclear cells, suggesting that it may also have anti-inflammatory effect that is highly relevant to the prevention immunopathology induced by SARS-CoV-2 infection.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFŒ± blockade is harmful to patients in the context of COVID-19.	-1	0.5
tomsdx3z	Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment	Herein we scrutinize a series of available studies by global scientists on the clinical manifestations, detection methods and treatment options of 2019 novel coronavirus pneumonia, also propose potential strategies for preventing the infection.	1	0.7704122673047837
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail.	-1	0.5
1mmqfp7g	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants ‚Ä†	Our analyses revealed that the top nine hits might serve as potential anti- SARS-CoV-2 lead molecules for further optimisation and drug development process to combat COVID-19.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough.	1	0.7704122673047837
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	However, in our prediction, they may also bind to the replication complex components of 2019-nCoV with an inhibitory potency with Kd < 1000 nM.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	The pandemic of COVID-19 has been taking lives worldwide.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19).	1	0.6078988077281519
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	(2) 50% of the patients' first symptoms were fever and cough; (3) The total number of white blood cells in peripheral blood was normal or decreased in 23 cases (79%), and the lymphocyte count decreased in 5 cases (13.89%), without anemia.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with Kd < 1,000 nM.	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	Our bioinformatic analysis showed a group of only six crRNAs can target more than 90% of all coronaviruses.	1	0.7704122673047837
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	A unique phenylalanine F486 in the flexible loop likely plays a major role because its penetration into a deep hydrophobic pocket in ACE2.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	According to COVID-19 prevention and control policy and requirements, combined with series of diagnosis and treatment plans, pharmacists in the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province in Northeast China have established the management practices of drug supply and pharmaceutical care from four aspects: personnel, drugs supply management, off-label drug use management and pharmaceutical care.	1	0.6078988077281519
6y9n69g5	Drug targets for corona virus: A systematic review	There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Recently, remarkable improvements in computational power coupled with advancements in Machine Learning (ML) technology have been utilized to revolutionize the drug development process.	-1	0.5
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials.	1	0.7571549044589717
sjyrr2bn	COVID-19: A promising cure for the global panic	Hence, the recent outburst of COVID-19 highlights an urgent need for therapeutics targeting SARS-CoV-2.	1	0.6078988077281519
fvig79k3	Predictions for the binding domain and potential new drug targets of 2019-nCoV	Furthermore, site prediction on the surface glycoprotein of 2019-nCoV suggests some core amino acid area may be a novel drug target against 2019-nCoV.	-1	0.5
ymc93p0w	The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15	These observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19.	1	0.7704122673047837
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	As of March 5, SARS-CoV-2 has killed 10 people in the US and infected nearly 100.	-1	0.5
0d77ojnb	The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding	This has implications for the rapid development of a first-line therapeutic by repurposing heparin and for next-generation, tailor-made, GAG-based antivirals.	1	0.7571549044589717
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	Combination of Ribavirin and Interferon-Œ± is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable.	1	0.7571549044589717
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	Our results show that darunavir has the best binding affinity with SARS-CoV-2 and SARS-CoV 3CLpro among all inhibitors, indicating it has the potential to become an anti-COVID-19 clinical drug.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	SwissADMET and Molinspiration Cheminformatics for CLogP (mean range of 0.77-8.72) of the lead compounds showed no correlation observed between lipophilicity and interaction with receptors and all the compounds except for baicalin exhibited drug-like properties based on Lipinski and Veber filter.	-1	0.5
5i2dxg8z	The 2019 novel coronavirus resource	Moreover, by linking seamlessly with related databases in CNCB/NGDC, 2019nCoVR offers virus data submission and sharing services for raw sequence reads and assembled sequences.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Fever (91.7%), cough (75.0%), fatigue (75.0%) and gastrointestinal symptoms (39.6%) were the most common clinical manifestations, whereas hypertension (30.0%) and diabetes mellitus (12.1%) were the most common comorbidities.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Individual data, laboratory indices, imaging characteristics, and clinical data were collected, and statistical analysis was performed.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Results: 32 confirmed cases that met the inclusion criteria were included.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	Compare the clinical characteristics of severe patients (including severe and critical patients) and non- severe patients (general patients).	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	In this review, the early use of TCM for light and ordinary patients, can rapidly improve symptoms, shorten hospitalization days and reduce severe cases transformed from light and normal.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Additional therapies included broad spectrum antibiotics (n=30), steroids (n=39) or various interferons (n=12).	-1	0.5
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	With a diagnosis of post-infectious acute myelitis and comprehensive treatment, paralysis of bilateral lower extremities ameliorated.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	We analyzed the demographic, epidemiological, clinical, and radiological features from those patients, and compared the difference between NCOVID-19 and NON-NCOVID-19.	-1	0.5
h8ahn8fw	Origin and Evolution of the 2019 Novel Coronavirus	It is necessary to further strengthen the monitoring to ensure that it will not cause diseases like Global Outbreak of 2003 SARS.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Results 28 COVID-19-infected cancer patients were included; 17 (60.7%) patients were male.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Next, a docking analysis was used to test whether the compound had the potential for direct 2019-nCoV interaction.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response.	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	We evaluate 11 complete genome sequence of different coronavirus using BAST and MAFFT software.	1	0.7704122673047837
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	9 patients were unconfirmed until a third-time nucleic acid test.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5.	-1	0.5
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	In particular, serum biomarkers, including urea, CREA, CysC, which reflect glomerular filtration function, may have some significance as potential indicators for the early diagnosis of severe COVID-19 and to distinguish it from mild COVID-19.	-1	0.5
k0te068l	Implications of COVID-19 for patients with pre-existing digestive diseases	Whether this finding is secondary to COVID-19 or a pre-existing gastrointestinal comorbidity is unknown.	-1	0.5
xuczplaf	The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak	In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	Moreover, in a large cohort including 1099 patients from 552 hospitals in 31 provinces or provincial municipalities, more severe patients with disease had abnormal liver aminotransferase levels than did non-severe patients with disease.1 Furthermore, in another study,8 patients who had a diagnosis of COVID-19 confirmed by CT scan while in the subclinical phase (ie, before symptom onset) had significantly lower incidence of AST abnormality than did patients diagnosed after the onset of symptoms.	-1	0.5
w9a0jopu	From Isolation to Coordination: How Can Telemedicine Help Combat the COVID-19 Outbreak?	Our ETCS has demonstrated substantial benefits in terms of the effectiveness of consultations and remote patient monitoring, multidisciplinary care, and prevention education and training.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	Here, to more precisely explore the potential pathogen transmission route of the 2019-nCoV infections in the gastrointestinal tract, we analyzed the ACE2 RNA expression profile in the colon tissue of healthy adults and colorectal cancer patients of our cohort and other databases.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	Many people are asymptomatic.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Findings Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation.	1	0.7704122673047837
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Selected epitopes indicated significant interactions with the HLA-binding alleles and 99.29% coverage of the world population.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	We comprehensively tested the pre-clinical immunogenicity of MERS-CoV vaccines in mice when delivered subcutaneously by traditional needle injection, or intracutaneously by dissolving microneedle arrays (MNAs) by evaluating virus specific IgG antibodies in the serum of vaccinated mice by ELISA and using virus neutralization assays.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	To enhance the immune response for our vaccine design, truncated (residues 10-153) Onchocerca volvulus activation-associated secreted protein-1 (Ov-ASP-1) has been utilized as an adjuvant at N terminal of both the MEVs.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Domestically in China, the virus has also been noted in several cities and provinces with cases in all but one provinence.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(13:41) - Risk communication: how do we present information so there's faith that it's accurate?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	As the virus is a newly emerging pathogen, many questions remain unanswered regarding the virus&rsquo;s reservoirs, pathogenesis, transmissibility, and much more is unknown.	-1	0.5
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19.	1	0.7704122673047837
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server.	-1	0.5
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Risk perception was low (median score of 5 out of 10) with the respondents trusting health professionals and health officials for information on COVID-19.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	It is worth mentioning that all of the 6 dominated epitopes were absolutely conservative in nearly 1000 SARS-CoV-2 genomes, and they deserved further study.	-1	0.5
1mjaycee	COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses	We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.	-1	0.5
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	The genetic analyses predict bats as the most probable source of 2019-nCoV though further investigations needed to confirm the origin of the novel virus.	-1	0.5
rziv5342	Prevention Is Better Than the Cure: Risk Management of COVID-19	COVID-19 is compared with two related coronavirus epidemics, SARS and MERS, in terms of the number of reported human infections, deaths, countries, major country clusters, timelines, and the likelihood of discovering a safe, effective, and approved vaccine.	1	0.7704122673047837
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	This article is protected by copyright.	-1	0.5
679qfp2s	Lack of Antiviral Activity of Darunavir against SARS-CoV-2	Overall, the data do not support the use of DRV for treatment of COVID-19.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	It was shown that the RBD-ACE2 binding free energy for 2019-nCoV is significantly lower than that for SARS-CoV, which is consistent with the fact that 2019-nCoV is much more infectious than SARS-CoV.	-1	0.5
c4u0gxp5	The outbreak of COVID-19: An overview	To promptly identify patients and prevent further spreading, physicians should be aware of the travel or contact history of the patient with compatible symptoms.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	In order to assess the potential of the Wuhan 2019-nCoV to cause maternal, fetal and neonatal morbidity and other poor obstetrical outcomes, this communication reviews the published data addressing the epidemiological and clinical effects of SARS, MERS, and other coronavirus infections on pregnant women and their infants.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Literature searches were performed using keywords including ‚ÄúCoronavirus 2019‚Äù, ‚Äú2019-nCoV‚Äù, ‚ÄúCOVID-19‚Äù, and ‚ÄúSARS-CoV-2‚Äù.	1	0.7704122673047837
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	While reports suggest that asymptomatic infection and transmission may result from minimally symptomatic cases, the contribution of this to transmission is not yet known.8 Careful analysis of early data suggests that the mean incubation period is 6 days, with a range of up to 14 days.9 Reports of large outbreaks, particularly associated with hospitals and closed communities, raise the possibility of ‚Äúsuperspreading‚Äù events, a feature of previous coronavirus outbreaks.10 The importance of infection control is also reinforced by a report that 41% of cases in Wuhan were acquired nosocomially (including 40 health care workers and 17 patients).4 As at 26 February 2020, there were 23 confirmed cases of COVID‚Äê19 in Australia, across five jurisdictions.	1	0.7704122673047837
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	We found that commercial S1 IgG or IgA ELISAs were of lower specificity while sensitivity varied between the two, with IgA showing higher sensitivity.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	The work can, nonetheless, be described in traditional bioinformatics terms, and readily reproduced by others, albeit with the caveat that new data and research into 2019-nCoV is emerging and evolving at an explosive pace.	-1	0.5
a5udnv5f	Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2	Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Special Topics 222(3-4), 2013) has proposed a novel measure known as Effort-To-Compress (ETC) based on the notion of compression-complexity to capture the information content of sequences.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	Our simulation results suggest that the association of new virus to the receptor is slower than SARS, which is consistent with the experimental data obtained very recently.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Participants: All Twitter users who created or sent a message from January 14th to 28th, 2020.	-1	0.5
wbxtz30s	After corona: there is life after the pandemic	Thus, performing ovarian stimulation and fertilization without delay, freezing the resulting embryos and delaying embryo transfer until the end of the pandemic appears to be the best strategy at present.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	Secondly, during the SARS-CoV epidemic, clinical reports have suggested tears as a medium of infection.	-1	0.5
5ekdfers	The phenotypic changes of Œ≥Œ¥ T cells in COVID-19 patients	In addition, the increased expression of CD4 in Œ≥Œ¥ T cells may serve as a biomarker for the assessment of SARS-CoV-2 infection.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	(‚Ä†) On January 31, the U.S. Department of Health and Human Services (HHS) Secretary declared a U.S. public health emergency to respond to 2019-nCoV.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Findings SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties.	1	0.6078988077281519
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	A total of 662 responses were received.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features.	-1	0.5
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants‚Äô clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV).	1	0.7704122673047837
vbayngh0	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	The crystal structures showed that 11a and 11b are irreversible, the aldehyde groups of which are bound covalently to Cys145 of Mpro.	-1	0.5
1qniriu0	Machine intelligence design of 2019-nCoV drugs	The potential effectiveness of treating 2019-nCoV by using some existing HIV drugs is also analyzed.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2X infection.	-1	0.5
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Further pharmacokinetic and toxicokinetic evaluation in rats and monkeys showed a high concentration of CVL218 in lung and observed no apparent signs of toxicity, indicating the appealing potential of this drug for the treatment of the pneumonia caused by SARS-CoV-2 infection.	1	0.6078988077281519
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest.	-1	0.5
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	In addition, we also found that several antiviral agents, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	It caused by a novel coronavirus which human being are lack of defensive function in whole population.	1	0.7704122673047837
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	We started from the structure, immunogenicity, and pathogenesis of coronavirus infections of the novel coronavirus.	1	0.7704122673047837
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Hypersensitive c-reactive protein increased in 19 (52.78%) cases, and procalcitonin increased in 1 case.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Materials and methods In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp.	-1	0.5
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2.	-1	0.5
xieqswct	Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza	The PAC-MAN approach is potentially a rapidly implementable pan-coronavirus strategy to deal with emerging pandemic strains.	1	0.7704122673047837
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	ACE2 is widely expressed with conserved primary structures throughout the animal kingdom from fish, amphibians, reptiles, birds, to mammals.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	During the outbreak, the pharmaceutical department of THJU completed its assigned workload to ensure drug supply.	1	0.6078988077281519
6y9n69g5	Drug targets for corona virus: A systematic review	The major structural proteins and NSPs may serve an important role from drug design perspectives.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Consequently, a detailed study using ML for the repurposing of therapeutic agents is urgently required.	-1	0.5
da61tfr9	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.	1	0.7571549044589717
sjyrr2bn	COVID-19: A promising cure for the global panic	Here, we have discussed the structure of virus; varying symptoms among COVID-19, SARS, MERS and common flu; the probable mechanism behind the infection and its immune response.	-1	0.5
cfbs29qo	CDC‚Äôs coronavirus test runs into early problems	Several hundred people have been tested, but the CDC has now stopped reporting testing numbers in favor of [truncated]	-1	0.5
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness.	-1	0.5
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	The likely reason behind the increased binding affinity of HIV-1 protease inhibitors toward SARS-CoV2 3CLpro than that of SARS-CoV were investigated by MD simulations.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	The ADMET profile showed that lead compounds lack hepatotoxicity and mutagenicity effects while they show variable immunotoxicity, carcinogenicity and cytotoxicity.	-1	0.5
5i2dxg8z	The 2019 novel coronavirus resource	In this report, we provide comprehensive descriptions on data deposition, management, release and utility in 2019nCoVR, laying important foundations in aid of studies on virus classification and origin, genome variation and evolution, fast detection, drug development and pneumonia precision prevention and therapy.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Drug hypersensitivity (11.4%) and urticaria (1.4%) were self-reported by several patients.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Based on clinical typing results, the patients were divided into a progression group or an improvement/stabilization group.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	28 cases were of mild or moderate type (87.50%), and four cases (12.50%) of severe or critical type.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	ResultsÔºö Of 51 hospitalized patients with COVID-19, the median age was 45 years (interquartile range, 34-51; range, 16-68 years) and 32 (62.7%) were men.43Ôºà84.3%Ôºâpatients had been to Wuhan or Other Hubei areas outside WuhanÔºåand 4Ôºà7.7%Ôºâ patients had a clear contact history of COVID-19 patients before the onset of the disease, and 4Ôºà7.7%Ôºâ patients had no clear epidemiological history of COVID-19.Common symptoms included fever (43 [84.3%]), cough (38 [74.5%]) and fatigue (22 [43.1%]).	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	Many TCM formulas and products have wide application in treating infectious and non-infectious diseases.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	No eligible studies examining monoclonal antibodies for COVID-19 were identified.	-1	0.5
ksbha7kz	Acute myelitis after SARS-CoV-2 infection: a case report.	After two times negative novel coronavirus RNA nasopharyngeal swabs tests, he was discharged and transferred to a designated hospital for isolation treatment and rehabilitation therapy.	1	0.7704122673047837
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	RESULTS: All patients had a history of exposure to confirmed case of 2019-nCoV or travel to Hubei before illness.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Median age was 65.0 years (IQR:56.0-70.0).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	In the second step we searched Chinese herbal databases to identify treatments containing the selected compounds.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection.	1	0.6078988077281519
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	We also selected 7 types of structural proteins.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	38 cases had a history of chronic diseases.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Patients hospitalized in the same period were observed as concurrent control.	-1	0.5
6rs86u5v	Potential biochemical markers to identify severe cases among COVID-19 patients	Glomerular filtration function injury in severe COVID-19 patients should also be considered by clinicians.	-1	0.5
penb65x7	Liver injury in COVID-19: management and challenges	Therefore, liver injury is more prevalent in severe cases than in mild cases of COVID-19.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	The data indicates that ACE2 is mainly expressed in epithelial cells of the colon.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The case fatality rate is estimated to range from 2 to 3%.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	The average age of the patients was 55¬∑5 years (SD 13¬∑1), including 67 men and 32 women.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals.	1	0.7704122673047837
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Finally, 505 amino acids long MEV was designed by connecting sixteen MHC class I and eleven MHC class II epitopes with suitable linkers and adjuvant.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Driven by the urgent need for COVID-19 vaccines, we utilized this strategy to rapidly develop MNA SARS-CoV-2 subunit vaccines and tested their pre-clinical immunogenicity in vivo by exploiting our substantial experience with MNA MERS-CoV vaccines.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	Further molecular models for both the MEVs were prepared and validated for their stable molecular interaction with Toll-Like Receptor 3 (TLR 3).	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	While zoonotic transmission appears to be the original source of infections, the most alarming development is that human-to-human transmission is now prevelant.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(15:24) - Risk groups (children, the elderly, pregnant women) (16:26) - Containment vs mitigation vs quarantine vs isolation (19:10) - Protecting the elderly and nursing home resident (23:52) - Public health prospects in Latin America, Africa (26:35) - Will coronavirus wane in warmer months like influenza?	1	0.7704122673047837
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	The collaborative efforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the proper diagnostic tools, and effective treatment to combat this infection.	-1	0.5
pidar1gz	Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases	The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	The structural divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein.	1	0.7704122673047837
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Majority of the respondents were in favor of strict infection prevention policies to control the outbreak.	-1	0.5
fmumym1x	Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2	The findings would facilitate the vaccine development, had the potential to be directly applied on the treatment in this disease, but also have the potential to prevent the possible threats caused by other types of coronavirus.	1	0.7704122673047837
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	The ongoing nCoV outbreak highlights the hidden wild animal reservoir of the deadly viruses and possible threat of spillover zoonoses as well.	-1	0.5
2tu707ng	Potential Interventions for Novel Coronavirus in China: A Systemic Review	All rights reserved.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	In addition, the spike protein of 2019-nCoV shows a significantly lower free energy than that of SARS-CoV, suggesting that 2019-nCoV is more stable and able to survive a higher temperature than SARS-CoV.	-1	0.5
iy9vjpuh	Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections	Recommendations are also made for the consideration of pregnant women in the design, clinical trials, and implementation of future 2019-nCoV vaccines.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Moreover, websites such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) were searched to retrieve updated data and statistics regarding the novel coronavirus.	1	0.7704122673047837
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	Although reported case numbers in China are slowing, large outbreaks on a cruise ship in Japan, and in South Korea, Iran and Italy are concerning and highlight our interconnected world.	-1	0.5
9595vm0k	SARS-CoV-2 specific antibody responses in COVID-19 patients	Overall, the validated assays described here can be instrumental for the detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiological and vaccine evaluation studies.	-1	0.5
13jupb26	Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus	Preliminary studies using molecular modeling and docking, and in that context the potential value of certain known herbal extracts, are also described.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	In this study, we propose a compression-complexity based distance measure for automatic identification of SARS coronavirus strains from a set of viruses using only short fragments of nucleotide sequences.	1	0.7704122673047837
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	We further integrated this difference of association rate between virus and receptor into a mathematical model which describes the life cycle of virus in host cells and its interplay with the innate immune system.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Measurements: We extracted tweets matching hashtags related to COVID-19 and measured frequency of keywords related to infection prevention practices, vaccination, and racial prejudice.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	In a case series by Loon et al., it was shown that viral RNA of the SARS-CoV can be detected by reverse-transcription polymerase chain reaction (RT-PCR) from the tears of infected individuals [9].	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	"(¬ß) Also on January 31, the president of the United States signed a ""Proclamation on Suspension of Entry as Immigrants and Nonimmigrants of Persons who Pose a Risk of Transmitting 2019 Novel Coronavirus,"" which limits entry into the United States of persons who traveled to mainland China to U.S. citizens and lawful permanent residents and their families (3)."	1	0.7704122673047837
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	The responders had a moderate level of knowledge about the COVID-19 infection and adequate knowledge about its preventive aspects.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses.	1	0.7704122673047837
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database.	-1	0.5
b4joa5tx	Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease	Both compounds are promising drug leads with clinical potential that merits further studies.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	The antiviral activities and antiviral mechanisms of potential drugs were further investigated.	-1	0.5
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Moreover, molecular docking simulation suggested that CVL218 may bind to the N-terminal domain of nucleocapsid (N) protein of SARS-CoV-2, providing a possible model to explain its antiviral action.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19.	1	0.7704122673047837
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	Possible targets of these compounds and potential drugs acting on a certain target were predicted.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China.	-1	0.5
cszqykpu	Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model	Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	It targets human‚Äôs lung and causes serious damage of lungs.	-1	0.5
b518n9dx	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	Further, we analyzed the pharmacological actions and previous trials of remdesivir to identify the feasibility of conducting experiments on COVID-19.	1	0.6078988077281519
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Albumin decreased in 5 cases (13.89%), proalbumin decreased in 15 cases (41.67%), alanine transaminase increased slightly in 4 cases (11.11%), alanine transaminase increased slightly in 4 cases (11.11%), total bilirubin increased slightly in 11 cases (30.56%), and renal function and blood coagulation were normal.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.	1	0.7571549044589717
zb434ve3	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	Structural analysis suggests that ACE2 from these animals can potentially bind RBD of 2019-nCoV, making them all possible natural hosts for the virus.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	So far, no nosocomial infections and medication errors have occurred, which has stabilized the mood of the staff and boosted the pharmacists' confidence in fighting the epidemic.	1	0.6078988077281519
6y9n69g5	Drug targets for corona virus: A systematic review	However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Here, we report the ML model based on the Naive Bayes algorithm, which has an accuracy of around 73% to predict the drugs that could be used for the treatment of COVID-19.	-1	0.5
sjyrr2bn	COVID-19: A promising cure for the global panic	Further, the current treatment options, drugs available, ongoing trials and recent diagnostics for COVID-19 have been discussed.	-1	0.5
p1w3p80y	Pharmacotherapeutics for the New Coronavirus Pneumonia	Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.	-1	0.5
m0hivi0u	Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro	Our study provides insight into the possible role of structural flexibility during interactions between 3CLpro and inhibitors, and sheds light on the structure-based design of anti-COVID-19 drugs targeting the SARS-CoV-2 3CLpro.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	The compounds Scopodulic acid and Dammarenolic acid showed the best-fit value of activity against SARS-CoV-2 spike glycoprotein 6vsb and main protease Mpro 6lu7 targets, respectively.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Asthma or other allergic diseases was not reported by any of the patients.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Continuous variables were analyzed using independent samples t-test or Mann-Whitney U test.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Four cases (12.5%) were combined with one underlying disease (bronchial asthma, coronary heart disease, malignant tumor, chronic kidney disease), and one case (3.13%) was simultaneously combined with high blood pressure and malignant tumor.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	Lymphopenia was observed in 26 patients (51.0%), and elevated C-reactive protein level in 32 patients (62.7%).	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	The TCM theoretical system of treating epidemic diseases with TCM and the treatment scheme of integrated Chinese and Western medicine have proved their effectiveness in clinical practice.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	One trial found that ribavirin prophylactic treatment statistically significantly reduced risk of MERS infection in people who had been exposed to the virus.	1	0.7571549044589717
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	The median duration, respectively, was 8 (IQR:6~11) and 5 (IQR:4~11) days from exposure to onset in NCOVID-19 and NON-NCOVID-19.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Lung cancer was the most frequent cancer type (7, 25.0%).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Plants containing 2 or more of the compounds identified in our screen were then checked against the catalogue for classic herbal usage.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort.	-1	0.5
qopcs6jy	Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future	We were conclude that COVID-19 might be created new mutations specifically in glycoproteins hence requires caution and complete preparation by health authorities.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	The main clinical manifestations of the patients were fever and cough, which accounted for 63 cases (78.75%) and 51 cases (-63.75%) respectively.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	The expression of ACE2 is gradually increased from healthy control, adenoma to colorectal cancer patients in our cohort as well as in the external Asian datasets.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	2019-nCoV was detected in all patients by real-time RT-PCR.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and linear B-cell epitopes localized in specific locations and functional domains of the protein.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Linkers and adjuvant were added to enhance the immunogenicity response of the MEV.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Findings Here we describe the development of MNA delivered MERS-CoV vaccines and their pre-clinical immunogenicity.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	Several vaccine candidates are in the pipeline.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The codon-optimized cDNA of both the MEVs were further analyzed for their potential of high level of expression in Human cell line.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Of particular concern is that many healthcare workers have been infected in the current epidemic.	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(27:52) - Why is anxiety so high about this disease?- Does the US have capacity to care for COVID19 infection?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	Recent advancements in plant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals rapidly in a short time.	1	0.6078988077281519
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Our data suggests that 2019-nCoV is newly spilled coronavirus into humans in China is closely related to SARS-CoV, which has only 12.8% of difference with SARS-CoV in S protein and has 83.9% similarity in minimal receptor-binding domain with SARS-CoV.	1	0.7704122673047837
yk9u4fvp	Perceptions of the Adult US Population regarding the Novel Coronavirus Outbreak	Conclusion: Given our results, the public health/scientific leadership should be at the forefront of the COVID-19 response to promote trust.	-1	0.5
1qkwsh6a	Emerging novel coronavirus (2019-nCoV)‚Äîcurrent scenario, evolutionary perspective based on genome analysis and recent developments	The successful virus isolation attempts have made doors open for developing better diagnostics and effective vaccines helping in combating the spread of the virus to newer areas.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	This may also provide insights into the evolution of 2019-nCoV because SARS-like coronaviruses are thought to have originated in bats that are known to have a higher body-temperature than humans.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	We extracted data on the epidemiology, pathogenesis, virology, clinical manifestations, transmission routes, diagnosis, treatment, and prevention measures.	-1	0.5
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	However, it is likely that this will change in the days or weeks ahead.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	We also demonstrate that our proposed method can correctly distinguish SARS-CoV-2 from SARS-CoV-1 viruses by analyzing very short segments of nucleotide sequences.	-1	0.5
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	Interestingly, we found that the slower association between virus and receptor can result in longer incubation period, while still maintaining a relatively higher level of viral concentration in human body.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	We performed a sentiment analysis to identify emotional valence and predominant emotions.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	While anecdotal in nature, such accounts highlight the possible infectivity of tears, a fluid which ophthalmologists and instruments come in contact on a daily basis.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	CDC, multiple other federal agencies, state and local health departments, and other partners are implementing aggressive measures to slow transmission of 2019-nCoV in the United States (4,5).	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	The titers of NAb among these patients correlated with the spike-binding antibodies targeting S1, RBD, and S2 regions.	-1	0.5
aeuy92bx	Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig	As these fusion proteins exhibit cross-reactivity against coronaviruses, they could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.	1	0.7704122673047837
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	The attitude towards COVID-19 showed peoples' willingness to follow government guidelines on quarantine and social distancing.	-1	0.5
qdt90c22	Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target	Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2.	1	0.6078988077281519
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM).	1	0.7571549044589717
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively.	-1	0.5
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	We also proposed several possible mechanisms to explain the antiviral activities of PARP1 inhibitors against SARS-CoV-2, based on the data present in this study and previous evidences reported in the literature.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	CONCLUSION: The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients.	-1	0.5
b31ctbat	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.	-1	0.5
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Based on early reports, for people with underlying heart issues, the concerns are serious.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Absolute value of CD3+T cells is with a decrease in 21 cases (58.3%), CD4+T in 28 cases (77.8%), CD8+T in 17 cases (47.2%), and CD4+/ CD8+ inverse in 6 cases (16.7%).	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Key findings The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.	1	0.7571549044589717
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	2019-nCoV is thought to be transmitted through respiratory droplets.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	For the treatment of COVID-19, pharmacists conducted adverse reaction monitoring and participated in the multidisciplinary consultation of COVID-19.	1	0.6078988077281519
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Our study predicts around ten FDA approved commercial drugs that can be used for repurposing.	-1	0.5
sjyrr2bn	COVID-19: A promising cure for the global panic	We suggest traditional Indian medicinal plants as possible novel therapeutic approaches, exclusively targeting SARS-CoV-2 and its pathways.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	Our data suggest silibinin a repurposing candidate drug may have multitarget activity against SARS-CoV-2.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Chronic obstructive pulmonary disease (COPD, 1.4%) and current smokers (1.4%) were rare.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Categorical variables were analyzed using Chi-squared test or Fisher exact test.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	The results of laboratory examination showed that the alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), and total bilirubin (TBil) for entire cohort were 26.98 (16.88 ~ 46.09) U/L and 24.75 (18.71 ~ 31.79) U/L, 39.00 (36.20 ~ 44.20) g/L and 16.40 (11.34- ~ 21.15) mmol/L, respectively.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	Ground-glass opacity was the typical radiological finding on chest computed tomography (41 [80.4%])ÔºåLocal consolidation of pneumonia in some patients(17 [33.3%]).Most of the patients were treated with traditional Chinese medicine decoction (28 [54.9%])Ôºåall of them received aerosol inhalation of recombinant human interferon a-1b for injection and oral antiviral therapy with Lopinavir and Ritonavir tablets (51 [100%]); Most of the patients were given Bacillus licheniformis capsules regulated intestinal flora treatment (44 [86.3%]).	-1	0.5
athjtu2j	Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection	TCM can cure COVID-19 pneumonia, and also shows that the role of TCM in blocking the progress of COVID-19 pneumonia.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Of the 21 studies reporting rates of ICU admission in hospitalized SARS or MERS patients, none reported statistically significant results in favour of or against antiviral therapies.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	The clinical symptoms were similar between NCOVID-19 and NON-NCOVID-19.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	8 (28.6%) patients were suspected to be from hospital-associated transmission.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Finally, network pharmacology analysis was used to predict the general in vivo effects of each selected herb.	1	0.6078988077281519
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Baricitinib has both antiviral and anti-inflammatory properties.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Only 3 patients (3.75%) showed liver dysfunction.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	According to the expression profile of ACE2 in colon epithelial cells, we speculate adenoma and colorectal cancer patients are more likely to be infected with 2019-nCoV than healthy people.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	Common laboratory findings include normal/ low white cell counts with elevated C-reactive protein (CRP).	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	50 (51%) patients had chronic diseases.	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	By applying reverse vaccinology and machine learning, we predicted potential vaccine targets for effective and safe COVID-19 vaccine development.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	The antigenicity, allergenicity, physiochemical properties and structural details of MEV were analyzed in order to ensure safety and immunogenicity.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Specifically, MNA delivered MERS-S1 subunit vaccines elicited strong and long-lasting antigen-specific antibody responses.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	The present study proposes in-silico validated design of two MEVs against SARS-CoV-2 to elicit humoral as well as cellular immune response.Graphical abstractThe designed CTL (Cytotoxic T lymphocyte) and HTL (Helper T lymphocyte) multi-epitope vaccine (MEV) against COVID19 infection.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	There are several critical clinical questions that need to be resolved, including how efficient is human-to-human transmission?	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(31:03) - What is your daily schedule like?	-1	0.5
gu2mt6zp	Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development	In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine development, and the potential of a plant system for biopharmaceutical development are discussed.	1	0.6078988077281519
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Addition of a novel glycosylation sites were observed in 2019-nCoV.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	It was also revealed that the RBD of 2019-nCoV is much more flexible especially near the binding site and thus will have a higher entropy penalty upon binding ACE2, compared to the RBD of SARS-CoV.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Results: From the 1416 articles identified in the initial search, 53 were remained after title and abstract screening.	-1	0.5
02f0opkr	An outbreak of <scp>COVID</scp> ‚Äê19 caused by a new coronavirus: what we know so far	Although absolute case numbers are small in Australia, the public health, political and societal ramifications have already been considerable, ranging from travel restrictions on non‚ÄêAustralians coming from China, the use of offshore and remote quarantine facilities, and disturbing reports of racism against members of our Asian community (https://insig‚Äãhtplus.mja.com.au/2020/5/coron‚Äãavirus-no-place-for-racism-xenop‚Äãhobia/).	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	This work could be extended further to enable medical practitioners in automatically identifying and characterizing SARS coronavirus strain in a fast and efficient fashion using short and/or incomplete segments of nucleotide sequences.	1	0.7704122673047837
535lw99y	A Multiscale and Comparative Model for Receptor Binding of 2019 Novel Coronavirus and the Implication of its Life Cycle in Host Cells	Our computational study therefore provides, from the molecular level, one possible explanation that the new disease by far spread much faster than SARS.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	We conducted topic modeling to identify and explore discussion topics over time.	-1	0.5
801t0728	Revisiting the dangers of the coronavirus in the ophthalmology practice	If true, this represents a crucial need for further development of disinfection and personal protective equipment (PPE) protocols for the ophthalmology clinic.SN - 1476-5454	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	These measures require the identification of cases and their contacts in the United States and the appropriate assessment and care of travelers arriving from mainland China to the United States.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	The titers of NAbs were variable in different patients.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	The anxiety levels identified in the study were high.	-1	0.5
vxqdfiel	Clinical trials on drug repositioning for COVID-19 treatment	Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.	1	0.6078988077281519
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	RESULTS: The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV.	1	0.7704122673047837
qebbkr6d	A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	In summary, the PARP1 inhibitor CVL218 discovered by our data-driven drug repositioning framework can serve as a potential therapeutic agent for the treatment of COVID-19.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19.	1	0.6078988077281519
0xhho1sh	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond.	-1	0.5
t996fbad	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury	ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available for this article at 10.1007/s11427-020-1643-8 and is accessible for authorized users.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	It appears people over 65 with coronary heart diseases or hypertension is more likely to be infected and to develop more severe symptoms.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	(4) The prealbumin, CD3 T cells, CD4 T cells and CD8 T cells in the new coronavirus pneumonia group were significantly lower than those in the normal control group, and the hypersensitive c-reactive protein was higher than that in the normal control group.	1	0.7704122673047837
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Significance The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	However, since ACE2 is predominantly expressed in intestines, testis, and kidney, fecal-oral and other routes of transmission are also possible.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	Up to now, the COVID-19 patients admitted to THJU have not shown any new serious adverse reactions and been cured finally.	-1	0.5
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Among all, we suggest that the antiretroviral drug Saquinavir (DrugBank ID DB01232) would probably be one of the most effective drugs based on the selected criterions.	-1	0.5
w84qtud6	Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets	So further in vitro and in vivo evaluations are recommended.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Bilateral ground glass or patchy opacity (89.6%) were the most common signs of radiological finding.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Logistic regression analysis was performed to explore the risk factors for disease progression.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	ALT, AST, ALB and TBil of the mild or moderate subgroups were 22.75 (16.31- ~ 37.25) U/L, 23.63 (18.71 ~ 26.50) U/L, 39.70 (36.50 ~ 46.10) g/L, and 15.95 (11.34 ~ 20.83) mmol/L, respectively.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	10 patients (19.6%) received short-term (3-5 days) glucocorticoid treatment.	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Of the 40 studies reporting mortality rates in hospitalized SARS or MERS patients, one cohort study (MERS) and one retrospective study (SARS) found a statistically significant increase in the mortality rate for patients treated with ribavirin.	1	0.7571549044589717
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	The most common symptoms were fever and cough.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	The following clinical features were shown in our cohort: fever (23, 82.1%), dry cough (22, 81%) and dyspnoea (14, 50.0%), along with lymphopaenia (23, 82.1%), high level of high-sensitivity C-reactive protein (23, 82.1%), anaemia (21, 75.0%) and hypoproteinaemia (25, 89.3%).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Results Of the natural compounds screened, 13 that exist in traditional Chinese medicines were also found to have potential anti-2019-nCoV activity.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Imaging examination showed that 55 patients (-68.75%) showed abnormal, 25 cases (31.25%) had no abnormal density shadow in the parenchyma of both lungs.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Findings:17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020.	-1	0.5
3r0nqzgu	Profiling ACE2 expression in colon tissue of healthy adults and colorectal cancer patients by single-cell transcriptome analysis	Our data may provide a theoretical basis for the classification and management of future 2019-nCoV susceptibility people in clinical application.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The computerized tomographic chest scan is usually abnormal even in those with no symptoms or mild disease.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient).	-1	0.5
ld0vo1rl	COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning	"We then propose that an ""Sp/Nsp cocktail vaccine"" containing a structural protein(s) (Sp) and a non-structural protein(s) (Nsp) would stimulate effective complementary immune responses."	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	MEV construct was non-allergenic, antigenic, stable and flexible.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Building on our ongoing efforts to develop MERS-CoV vaccines, promising immunogenicity of MNA-delivered MERS-CoV vaccines, and our experience with MNA fabrication and delivery, including clinical trials, we rapidly designed and produced clinically-translatable MNA SARS-CoV-2 subunit vaccines within 4 weeks of the identification of the SARS-CoV-2 S1 sequence.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV.	1	0.6078988077281519
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	Both the CTL and HTL MEVs models show a very sytable and very fitting conformational complex formation tendency with the Toll like receptor 3.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	What is the animal reservoir?	-1	0.5
nror02j6	COVID-19 Update ‚Äì March 2020 | Global Health | JN Learning | JAMA Ed Hub [Video recording]	(32:23)	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	In addition, antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	That means that 2019-nCoV will be much more temperature-sensitive in terms of human infection than SARS-CoV.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	After full-text review, 37 articles were eligible to include in our study.	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	Potentially, the need for sequence assembly can be circumvented.NoteThe main ideas and results of this research were first presented at the International Conference on Nonlinear Systems and Dynamics (CNSD-2013) held at Indian Institute of Technology, Indore, December 12, 2013.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Results: We evaluated 126,049 tweets from 53,196 unique users.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	These measures are being implemented in anticipation of additional 2019-nCoV cases in the United States.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Elderly and middle-age patients had significantly higher plasma NAb titers (P<0.0001) and spike-binding antibodies (P=0.0003) than young patients.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	More than 80 % of the people were preoccupied with the thoughts of COVID-19 and 72 % reported the need to use gloves, and sanitizers.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Three drugs-cepharanthine (CEP), selamectin and mefloquine hydrochloride exhibited complete inhibition of cytopathic effects in cell culture at 10 Œºmol/L.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	In addition, some of hospitalized COVID-19 patients had cardiovascular diseases in China.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	(5) The levels of PAB in the serum of the patients were linearly correlated with hs-crp, CD3 T cells, CD4 T cells and CD8 T cells, and the correlation coefficients were -0.474, 0.558, 0.467 and 0.613, respectively, showing statistical differences.	-1	0.5
d7n1zy0b	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.	-1	0.5
647zcjgu	Structure analysis of the receptor binding of 2019-nCoV	Finally, antibodies and small molecular inhibitors that can block the interaction of ACE2 with RBD should be developed to combat the virus.	-1	0.5
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	The hospital pharmacy department timely adjusted the work mode, and the formed management practices is a powerful guarantee for the prevention and control of the COVID-19 epidemic.	1	0.6078988077281519
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	Our study can help clinical scientists in being more selective in identifying and testing the therapeutic agents for COVID 19 treatment.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Lymphopenia (75.4%) and eosinopenia (52.9%) were observed in most patients.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	RESULTS: Seventy-eight patients with COVID-19-induced pneumonia met the inclusion criteria and were included in this study.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	ALT, AST, ALB and TBil of the severe or critical subgroups were 60.25 (40.88 ~ 68.90) U/L, 37.00 (20.88 ~ 64.45) U/L, 35.75 (28.68 ~ 42.00) g/L, and 20.50 (11.28 ~ 25.00) mmol/L, respectively.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	Compared with non-severe patients (n = 44), severe patients (n = 7) were older (median age, 52 years vs 44 years), had a higher proportion of diabetes mellitus (4 [57.1%] vs 0 [0.0%]), most of them needed antibiotic treatment (7 [100%] vs 4 [9.1%], most of them needed nutritional diet (6 [85.7%) vs 0 [0.0%], and were more likely to have dyspnea (6 [85.7%] vs 5 [11.4%])Ôºåmost of them needed noninvasive mechanical ventilation (6 [85.7%] vs 0 [0.0%]).	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Eighteen studies reported potential drug-related adverse effects including gastrointestinal symptoms, anemia, and altered liver function in patients receiving ribavirin.	1	0.7571549044589717
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	Fifteen (78.95%) NCOVID-19 but 4 (26.67%) NON-NCOVID-19 patients had bilateral involvement while 17 (89.47%) NCOVID-19 but 1 (6.67%) NON-NCOVID-19 patients had multiple mottling and ground-glass opacity of chest CT images.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	The common chest CT findings were ground-glass opacity (21, 75.0%) and patchy consolidation (13, 46.3%).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Further, 125 Chinese herbs were found to contain 2 or more of these 13 compounds.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Up to now, 21 cases were discharged from the hospital, and no patient died.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	11 hospitalized patients served as concurrent control.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	Treatment is essentially supportive; role of antiviral agents is yet to be established.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Molecular docking followed by molecular dynamics (MD) simulation analysis, demonstrated a stable and strong binding affinity of MEV with human pathogenic toll-like receptors (TLR), TLR3 and TLR8.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Most importantly, these MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses that were evident beginning 2 weeks after immunization.	-1	0.5
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	CTL and HTL MEVs: ribbon; Toll like receptor 3: gray cartoon; Adjuvant [truncated (residues 10-53).	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Is there an intermediate animal reservoir?	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	In spite of the variation in S protein amino acid composition, we found no significant difference in their structures.	-1	0.5
szsb1oan	The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China	Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	With the rising temperature, 2019-nCoV is expected to decrease its infection ability much faster than SARS-CoV, and get controlled more easily.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Incubation period for COVID-19 is between 2-10 days, according to the World Health Organization (WHO).	-1	0.5
ljli6a2z	Automatic Identification of SARS Coronavirus using Compression-Complexity Measures	In this manuscript, we have extended our preliminary analysis to include SARS-CoV-2 virus as well.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	The hourly number of COVID-19-related tweets starkly increased from January 21, 2020 onward.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	Although these measures might not prevent the eventual establishment of ongoing, widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare health care systems and the general public to be ready if widespread transmission with substantial associated illness occurs; and 3) better characterize 2019-nCoV infection to guide public health recommendations and the development of medical countermeasures including diagnostics, therapeutics, and vaccines.	1	0.6078988077281519
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Notably, among these patients, there were ten patients whose NAb titers were under the detectable level of our assay (ID50: < 40); while in contrast, two patients, showed very high titers of NAb, with ID50 :15989 and 21567 respectively.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	In this study, sleep difficulties, paranoia about acquiring COVID-19 infection and distress related social media were reported in 12.5 %, 37.8 %, and 36.4 % participants respectively.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 Œºmol/L.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFŒ± agents are contraindicated.	1	0.6078988077281519
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	As characteristic analysis of COVID-19 patients, hypertension and severe myocardial damage contribute to severity [1] and mortality of COVID-19 patients [2].	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Conclusion: The clinical characteristics of the novel coronavirus pneumonia in Kunming are different from those in Wuhan.	1	0.7704122673047837
7jkzbmsf	Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic	This paper summarized the details and practices of drug supply and pharmaceutical services management to provide experience for the people who involving in COVID-19 prevention and contain in other abroad epidemic areas.	1	0.6078988077281519
m0q7rm6z	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	The ML based approach for drug discovery as reported here can be a futuristic smart drug designing strategy for community applications.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Blood eosinophil counts correlate positively with lymphocyte counts in severe (r=0.486, p<0.001) and non-severe (r=0.469, p<0.001) patients after hospital admission.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Efficacy evaluation at 2 weeks after hospitalization indicated that 11 patients (14.1%) had deteriorated, and 67 patients (85.9%) had improved/stabilized.	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Conclusion: The results of this multicenter retrospective study suggests that novel coronavirus pneumonia combined with liver damage is more likely to be caused by adverse drug reactions and systemic inflammation in severe patients receiving medical treatment.	1	0.7704122673047837
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	Except one patient died, the remaining 50 patients were discharged according to the discharge standard, the common clinical symptoms disappeared basically, the lymphocyte increased significantly (P=0.008), CRP decreased significantly (P <0.001).	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	Conclusion: The current evidence for the effectiveness and safety of antiviral therapies for coronavirus is inconclusive and suffers from a lack of well-designed prospective trials or observational studies, preventing any treatment recommendations from being made.	1	0.7704122673047837
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	Compared to NON-NCOVID-19, NCOVID-19 present remarkably more abnormal laboratory tests including AST, ALT, Œ≥-GT, LDH and Œ±-HBDH.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	15 (53.6%) patients had severe events and mortality was 28.6%.	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Of these 125 herbs, 26 are classically catalogued as treating viral respiratory infections.	-1	0.5
nn15iyqd	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	National and international registries are being created to collect data on rheumatic patients with CoViD-19.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	The average length of stay for discharged patients was 8 days.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Baseline characteristics were generally balanced across two groups.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Codon optimization and in silico cloning of MEV ensured increased expression in the Escherichia coli K-12 system.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Interpretation MNA delivery of coronaviruses-S1 subunit vaccines is a promising immunization strategy against coronavirus infection.	1	0.7704122673047837
8gncbgot	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review	However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.	-1	0.5
80m78jh2	Structural basis to design multi-epitope vaccines against Novel Coronavirus 19 (COVID19) infection, the ongoing pandemic emergency: an in silico approach	Onchocerca volvulus activation-associated secrete protein-1]: orange ribbon; Epitopes: cyan ribbons regions; 6xHis Tag: magenta ribbon region	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Do the vaccines generated to the SARS-CoV or MERS-CoV or their proteins offer protection against 2019-nCoV?	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Collectively, for the first time our results exhibit the emergence of human 2019-nCoV is closely related to predecessor SARS-CoV and provide the evidence that 2019-nCoV uses various novel glycosylation sites as SARS-CoV and may have a potential to become pandemic owing its antigenic discrepancy.	-1	0.5
hicqy5sj	Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV)	The present findings are expected to be helpful for the disease prevention and control as well as drug and vaccine development of 2019-nCoV.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	The case fatality rate in patients infected with SARC-CoV-2 is 4.3%, and the results indicate that the mortality is higher in elderly individuals and patients with chronic conditions including patients with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Nearly half (49.5%) of all tweets expressed fear and nearly 30% expressed surprise.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	Public health authorities are monitoring the situation closely.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	The NAb titers were positive correlated with plasma CRP levels but negative correlated with the lymphocyte counts of patients at the time of admission, indicating an association between humoral response and cellular immune response.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	The perceived mental healthcare need was seen in more than 80 % of participants.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	The viral RNA yield in cells treated with 10 Œºmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ¬± 0.02] √ó 10vs.	-1	0.5
za3qypgg	Associations between immune-suppressive and stimulating drugs and novel COVID-19‚Äîa systematic review of current evidence	There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.	-1	0.5
13akn7dm	A close-up on COVID-19 and cardiovascular diseases	Therefore, to better understand the development of COVID-19 and the impacts of cardiovascular diseases will add valuable measures to the management of COVID-19 patients.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	The changes of serum proalbumin and T cell subsets are relatively obvious.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Significantly higher levels of D-dimer, C-reactive protein and procalcitonin were associated with severe patients compared to non-severe patients (all p<0.001).	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	The patients in the progression group were significantly older than those in the disease improvement/stabilization group (66 [51, 70] vs. 37 [32, 41] years, U = 4.932, P = 0.001).	-1	0.5
8o6yjxwe	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	Therefore, liver function monitoring and evaluation should be strengthened during the treatment of such patients.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	The median length of stay was 12 days (IQR, 9-13).	-1	0.5
ptnmtvzj	Effectiveness and safety of antiviral or antibody treatments for coronavirus	However, it is clear that the existing body of evidence is weighted heavily towards ribavirin (41/54 studies), which has not shown conclusive evidence of effectiveness and may cause harmful adverse events so future investigations may consider focusing on other candidates for antiviral therapy.	1	0.7571549044589717
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	CONCLUSION: The 2019-nCoV infection caused similar onsets to other pneumonias.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	If the last anti-tumour treatment was within 14 days, it significantly increased the risk of developing severe events (HR=4.079, 95%CI 1.086-15.322, P=0.037).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Network pharmacology analysis predicted that the general in vivo roles of these 26 treatments were related to regulating viral infection, immune/inflammation reactions and hypoxia response.	1	0.6078988077281519
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	CONCLUSIONS: Compared with the cases in Wuhan, the cases in Jiangsu exhibited mild or moderate symptoms and no obvious gender susceptivity.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients.	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality.	1	0.7704122673047837
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Interpretation The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	Designed MEV in present study could be a potential candidate for further vaccine production process against COVID-19.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Progressive scientific and technological efforts enable quicker responses to emerging pandemics.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	We offer a research perspective on the next steps for the generation of vaccines.	-1	0.5
b1iyr42n	Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)	Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	The mortality rate in healthy subjects is less than 1%.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	The frequency of racially charged tweets closely paralleled the number of newly diagnosed cases of COVID-19.	-1	0.5
vj2z52vg	Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak ‚Äî United States, December 31, 2019‚ÄìFebruary 4, 2020	As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC and state and local health departments.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Interpretation The variations of SARS-CoV-2 specific NAbs in recovered COVID-19 patients may raise the concern about the role of NAbs on disease progression.	-1	0.5
0lyxvex0	Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic	There is a need to intensify the awareness and address the mental health issues of people during this COVID-19 pandemic.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	1.00 ¬± 0.12, t = 150.38, P < 0.001) at 72 h post-infection (p.i.).	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	Changes in serum proalbumin may contribute to the early warning of novel coronavirus pneumonia.	1	0.7704122673047837
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	CONCLUSION: Detailed clinical investigation of 140 hospitalized COVID-19 cases suggest eosinopenia together with lymphopenia may be a potential indicator for diagnosis.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	The progression group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group (27.3% vs. 3.0%, œá = 9.291, P = 0.018).	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	ConclusionÔºöIn 51 single center cases confirmed as COVID-19 and discharged from the hospital, 13.7% of the patients were severe.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	CT scan may be a reliable test for screening NCOVID-19 cases.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Furthermore, patchy consolidation on CT on admission was associated with a higher risk for developing severe events (HR=5.438, 95%CI 1.498-19.748, P=0.010).	-1	0.5
gy35gsl2	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	Conclusion Chinese herbal treatments classically used for treating viral respiratory infection might contain direct anti-2019-nCoV compounds.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	The proportion of patients having liver dysfunction and abnormal CT imaging was relatively lower than that of Wuhan.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]).	-1	0.5
ztcyvsoi	A Review of Coronavirus Disease-2019 (COVID-19)	The global impact of this new epidemic is yet uncertain.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.	-1	0.5
2uvibr2j	Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches	However, to ensure its safety and immunogenic profile, the proposed MEV needs to be experimentally validated.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Our ongoing efforts to develop MNA-MERS-S1 subunit vaccines enabled us to rapidly design and produce MNA SARS-CoV-2 subunit vaccines capable of inducing potent virus-specific antibody responses.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	We also present data on the use of in silico docking in gaining insight into 2019-nCoV Spike-receptor binding to aid in therapeutic development.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Conclusion: The outbreak caused by the novel coronavirus is larger than the previous human coronaviruses, showing that the SARS-CoV-2 is an extremely contagious virus.	1	0.7704122673047837
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	The economic and political impact of the COVID-19 was the most commonly discussed topic, while public health risk and prevention were among the least discussed.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	The correlation of NAb titers with age, lymphocyte counts, and blood CRP levels suggested that the interplay between virus and host immune response in coronavirus infections should be further explored for the development of effective vaccine against SARS-CoV-2 virus.	1	0.7704122673047837
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Plaque assays found no production of live viruses in media containing 10 Œºmol/L CEP at 48 h p.i.	-1	0.5
p5ecpcll	Analysis on the Clinical Characteristics of 36 Cases of Novel Coronavirus Pneumonia in Kunming	The nutritional status of patients with common and mild pneumonia should be considered.	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Allergic diseases, asthma and COPD are not risk factors for SARS-CoV-2 infection.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	For all the 78 patients, fever was the most common initial symptom, and the maximum body temperature at admission was significantly higher in the progression group than in the improvement/stabilization group (38.2 [37.8, 38.6] vs. 37.5 [37.0, 38.4]¬∞C, U = 2.057, P = 0.027).	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	The main clinical symptoms of patients with COVID-19 were fever, cough and astheniaÔºåSome patients had obvious dyspnea.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	Liver function damage is more frequent in NCOVID-19 than NON-NCOVID-19 patients.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	Conclusions Cancer patients show deteriorating conditions and poor outcomes from the COVID-19 infection.	-1	0.5
hi38itc9	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study	Notably, infected patients may be falsely excluded based on two consecutively negative respiratory pathogenic nucleic acid test results.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection.	-1	0.5
yb5kf0u2	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	Collectively, our results support the clinical development of MNA delivered recombinant protein subunit vaccines against SARS, MERS, COVID-19, and other emerging infectious diseases.	-1	0.5
rxrlbw60	2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness	Diagnostic PCR protocols can be found at https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus.	1	0.7704122673047837
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	However, the mortality rate of COVID-19 is lower than that of other coronaviruses diseases such as SARS or MERS and other viruses like HIV and Ebola.	1	0.7704122673047837
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Conclusion: Tweets with negative sentiment and emotion parallel the incidence of cases for the COVID-19 outbreak.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Furthermore, titration of NAb is helpful prior to the use of convalescent plasma for prevention or treatment.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Furthermore, we found CEP has potent antiviral activities against both viral entry (1.00 ¬± 0.37 vs. 0.46 ¬± 0.12, t = 2.42, P < 0.05) and viral replication (1.00 ¬± 0.43 vs. [6.18 ¬± 0.95] √ó 10, t = 3.98, P < 0.05).	-1	0.5
5xyt8d5u	Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China	Elder age, high number of comorbidities and more prominent laboratory abnormalities were associated with severe patients.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Moreover, the proportion of patients with respiratory failure (54.5% vs. 20.9%, œá = 5.611, P = 0.028) and respiratory rate (34 [18, 48] vs. 24 [16, 60] breaths/min, U = 4.030, P = 0.004) were significantly higher in the progression group than in the improvement/stabilization group.	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	They had clinical laboratory and radiologic characteristics.	-1	0.5
6lngz7y1	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias	LDH and Œ±-HBDH may be considerable markers for evaluation of NCOVID-19.	-1	0.5
190zxwwj	Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China	It is recommended that cancer patients receiving anti-tumour treatments should have vigorous screening for COVID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 co-infection.	1	0.6078988077281519
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	No adverse effect was found in meplazumab-treated patients.	-1	0.5
m40kwgcg	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study	Funding National Key R&D Program of China.	-1	0.5
ejg393zs	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century	Currently, due to the lack of an effective treatment and vaccine, the best way to deal with the COVID-19 disease is to prevent transmission and spread of the virus and to execute personal protective measures.	-1	0.5
a6p6ka8w	"An ""Infodemic"": Leveraging High-Volume Twitter Data to Understand Public Sentiment for the COVID-19 Outbreak"	Twitter is a rich medium that can be leveraged to understand public sentiment in real-time and target public health messages based on user interest and emotion.	-1	0.5
uifnjio5	Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications	Funding Ministry of Science and Technology of China, National Natural Science Foundation of China, Shanghai Municipal Health Commission, and Chinese Academy of Medical Sciences	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	CONCLUSIONS: Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research.	1	0.7704122673047837
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	C-reactive protein was significantly elevated in the progression group compared to the improvement/stabilization group (38.9 [14.3, 64.8] vs. 10.6 [1.9, 33.1] mg/L, U = 1.315, P = 0.024).	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	There is no specific drug treatment for the disease.	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	CEP, selamectin and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Albumin was significantly lower in the progression group than in the improvement/stabilization group (36.62 ¬± 6.60 vs. 41.27 ¬± 4.55 g/L, U = 2.843, P = 0.006).	-1	0.5
yqiggzk9	Clinical characteristics of 51 patients discharged from hospital with COVID-19 in ChongqingÔºåChina	For the treatment of COVID-19, in addition to oxygen inhalation and antiviral treatment, attention should be paid to the dialectical treatment of traditional Chinese medicine, regulation of intestinal flora, nutritional support treatment and other comprehensive treatment.	1	0.7571549044589717
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia.	-1	0.5
z0qzgu5m	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and clinical trial of CEP for treatment of 2019-nCoV infection is warranted.	1	0.7704122673047837
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Patients in the progression group were more likely to receive high-level respiratory support than in the improvement/stabilization group (œá = 16.01, P = 0.001).	-1	0.5
6g34qwer	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Funding:National Science and Technology Major Project.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	Multivariate logistic analysis indicated that age (odds ratio [OR], 8.546; 95% confidence interval [CI]: 1.628-44.864; P = 0.011), history of smoking (OR, 14.285; 95% CI: 1.577-25.000; P = 0.018), maximum body temperature at admission (OR, 8.999; 95% CI: 1.036-78.147, P = 0.046), respiratory failure (OR, 8.772, 95% CI: 1.942-40.000; P = 0.016), albumin (OR, 7.353, 95% CI: 1.098-50.000; P = 0.003), and C-reactive protein (OR, 10.530; 95% CI: 1.224-34.701, P = 0.028) were risk factors for disease progression.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	CONCLUSIONS: Several factors that led to the progression of COVID-19 pneumonia were identified, including age, history of smoking, maximum body temperature on admission, respiratory failure, albumin, C-reactive protein.	-1	0.5
566pbuic	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease	These results can be used to further enhance the ability of management of COVID-19 pneumonia.	-1	0.5
